



(11)

**EP 3 052 131 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**05.12.2018 Bulletin 2018/49**

(51) Int Cl.:  
**C07K 16/28** <sup>(2006.01)</sup> **A61K 39/395** <sup>(2006.01)</sup>  
**A61K 35/00** <sup>(2006.01)</sup> **C12Q 1/6886** <sup>(2018.01)</sup>  
**G01N 33/574** <sup>(2006.01)</sup>

(21) Application number: **14850189.3**

(86) International application number:  
**PCT/US2014/053870**

(22) Date of filing: **03.09.2014**

(87) International publication number:  
**WO 2015/050663 (09.04.2015 Gazette 2015/14)**

(54) **METHODS FOR TREATING CANCER IN PATIENTS WITH ELEVATED LEVELS OF BIM**

VERFAHREN ZUR KREBSBEHANDLUNG BEI PATIENTEN MIT ERHÖHTEM BIM-SPIEGEL

PROCÉDÉS DE TRAITEMENT DU CANCER CHEZ DES PATIENTS PRÉSENTANT DES TAUX  
ÉLEVÉS DE BIM

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR**

(56) References cited:  
**WO-A1-2013/090552 US-A1- 2009 304 711  
US-A1- 2010 285 039**

(30) Priority: **01.10.2013 US 201361885218 P**

(43) Date of publication of application:  
**10.08.2016 Bulletin 2016/32**

(73) Proprietor: **Mayo Foundation for Medical  
Education and Research  
Rochester, MN 55905 (US)**

(72) Inventors:  
• **DONG, Haidong**  
**Rochester, Minnesota 55902-2533 (US)**  
• **HARRINGTON, Susan M.**  
**Rochester, Minnesota 55901 (US)**  
• **KWON, Eugene D.**  
**Rochester, Minnesota 55902 (US)**  
• **KRCO, Christopher J.**  
**Rochester, Minnesota 55901 (US)**  
• **LIU, Xin**  
**Rochester, Minnesota 55901 (US)**

(74) Representative: **Kunz, Herbert et al**  
**Fish & Richardson P.C.**  
**Highlight Business Towers**  
**Mies-van-der-Rohe-Straße 8**  
**80807 München (DE)**

- **TOPALIAN SUZANNE L ET AL: "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.", THE NEW ENGLAND JOURNAL OF MEDICINE 28 JUN 2012, vol. 366, no. 26, 28 June 2012 (2012-06-28), pages 2443-2454, XP002767416, ISSN: 1533-4406**
- **BERRIEN-ELLIOTT MELISSA M ET AL: "Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.", CANCER RESEARCH 15 JAN 2013, vol. 73, no. 2, 15 January 2013 (2013-01-15), pages 605-616, XP002767417, ISSN: 1538-7445**
- **RACHEL M GIBBONS ET AL: "B7-H1 limits the entry of effector CD8 + T cells to the memory pool by upregulating Bim", ONCOIMMUNOLOGY, vol. 1, no. 7, 1 October 2012 (2012-10-01) , pages 1061-1073, XP055332328, DOI: 10.4161/onci.20850**
- **GIBBONS ET AL.: 'B7-H1 limits the entry of effector CD 8+ T cells to the memory pool by upregulating Bim.' ONCOIMMUNOLOGY vol. 1, no. 7, 2012, pages 1061 - 1073, XP055332328**
- **DRONCA ROXANA S ET AL: "BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma.", IMMUNOTHERAPY DEC 2016, vol. 8, no. 12, December 2016 (2016-12), pages 1351-1353, ISSN: 1750-7448**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 052 131 B1**

- DRONCA ROXANA S ET AL: "T cell Bim levels reflect responses to anti-PD-1 cancer therapy.", JCI INSIGHT 05 MAY 2016, vol. 1, no. 6, 5 May 2016 (2016-05-05),

**Description****TECHNICAL FIELD**

5     **[0001]** This document relates to materials and methods for treating cancer, and more particularly to materials and methods for treating cancer in patients identified as having elevated levels of Bim.

**BACKGROUND**

10    **[0002]** The metastatic spread of tumor cells is the primary cause of cancer related mortality, indicating a need for therapeutic approaches capable of controlling or preventing metastasis (Gibbons et al. (2012) *Oncolimmunology* 1(7):1061-1073; and Grivennikov et al. (2010) *Cell* 140:883-899). The presence of tumor-infiltrating effector and memory T cells is correlated with decreased metastatic spread, consistent with a role for T cells in preventing metastasis of primary tumors.

15    **[0003]** B7-H1 (also referred to as PD-L1) is a polypeptide expressed by a variety of tumor cells. It also is constitutively expressed by macrophages and dendritic cells, and its expression is up-regulated upon cell activation. PD-1 is expressed on the surface of activated T cells, B cells, and macrophages, and is a receptor for B7-H1. CD80 is found on activated B cells and monocytes, and provides a costimulatory signal necessary for T cell activation and survival; CD80 also binds B7-H1.

20    **[0004]** Topalian SL et al. describe in *The New England Journal of Medicine*, vol. 366, no. 26, 28 June 2012, on pages 2443-2454 the safety, activity, and immune correlates of an anti-PD-1 antibody in cancer. WO 2013/090552 A1 describes compositions and methods for the therapeutic intervention of signaling through EP2 and EP4, in combination with the therapeutic intervention of signaling through PD-1, by inhibiting at least one of EP2, EP4, PGE2, or combinations thereof, in combination with inhibiting at least one of PD-1, PD-L1, PD-L2, and combinations thereof.

25    **[0005]** Berrien-Elliott MM et al. describe in *Cancer Research*, vol. 73, no. 2, 15 January 2013, on pages 605-616, a durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.

30    **[0006]** Gibbons RM et al. describe in *Oncoimmunology* vol. 1, no. 7, 1 October 2012, on pages 1061-1073 that B7-H1 limits the entry of effector CD8+ T cells to the memory pool by upregulating Bim.

**SUMMARY**

**[0007]** The present invention is defined by independent claim 1. The dependent claims depict other embodiments of the invention.

35    **[0008]** This document provides, *inter alia*, a method for determining whether PD-1 on T cells has engaged its ligand, B7-H1. The method is based in part on the discovery that engagement of PD-1 by B7-H1 results in up-regulation of Bim, a pro-apoptotic molecule, and is correlated with B7-H1-mediated T cell death. This discovery suggests that intracellular levels of Bim among PD-1 positive cells is a barometer of the extent to which PD-1 has been triggered by B7-H1, with lower levels of Bim identifying activated PD-1 positive T cells whose PD-1 molecules have not yet been extensively engaged, and higher levels of Bim reflecting chronic engagement of PD-1 with B7-H1. Stratifying Bim levels among PD-1 positive CD8 T cells may be a biomarker for gauging (1) whether PD-1 molecules on CD8 T cells have been engaged by B7-H1 tumor associated ligands; and (2) the efficacy of an anti-PD-1 or anti-B7-H1 blockade regimen in reducing PD-1 engagement. Thus, using Bim as a signaling biomarker for PD-1 function, it may be possible to select patients more likely to benefit from checkpoint blockade therapy and to identify optimal therapeutic timing and dosing schedules.

45    **[0009]** In one aspect, this document features a composition for use in a method for treating a mammal having cancer, wherein said method comprises: (a) identifying said mammal as containing an elevated level of Bim, and (b) administering to said mammal an anti-B7-H1 antibody, an anti-PD-1 antibody, an anti-CD80 antibody, a fusion protein comprising a portion of PD-1 linked to an immunoglobulin Fc sequence, or a fusion protein comprising a portion of CD80 linked to an Ig Fc sequence, under conditions wherein the interaction of naturally-occurring B7-H1 with PD-1 or CD80 in said mammal is reduced after said administering. The mammal can be a human. The cancer can be a melanoma cancer, a breast cancer, a lung cancer, a renal cell carcinoma cancer, a pancreas cancer, a prostate cancer, a colon cancer, a brain cancer, a liver cancer, or an ovarian cancer.

50    **[0010]** Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

**[0011]** The details of one or more embodiments of the invention are set forth in the accompanying drawings and the

description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

## DESCRIPTION OF DRAWINGS

[0012]

FIG. 1 contains a pair of graphs plotting the kinetics of CD8<sup>+</sup> T-cell responses to antigen stimulation. Wild type (WT) and B7-H1-deficient (KO) mice were immunized (i.p.) with OVA plus poly I:C, and K<sup>b</sup>/OVA tetramer was used to identify antigen-specific CD8<sup>+</sup> T cells in spleen (top panel) and liver (bottom panel) at the indicated times after immunization. Data show the percentage of tetramer<sup>+</sup> CD8<sup>+</sup> T cells (mean  $\pm$  SD of three mice per time point). One of two independent experiments is shown. \*p < 0.05 compared with WT mice.

FIGS. 2A-2D contain a series of FACS scans and graphs showing enhanced memory CD8<sup>+</sup> T-cell population in the absence of B7-H1. Mice were immunized with OVA plus poly I:C, and were re-stimulated with OVA on day 40 after immunization. On day 4 after re-stimulation, spleen cells were isolated from naive or immunized WT and B7-H1-deficient mice for analysis. FIG. 2A, FACS scans showing the percentage of OVA-specific tetramer<sup>+</sup> CD8<sup>+</sup> T cells; \*p < 0.05 compared with WT mice. FIG. 2B graph plotting the absolute number of OVA-specific tetramer<sup>+</sup> CD8<sup>+</sup> T cells (mean  $\pm$  SD, n = 3). FIG. 2C, FACS analysis of intracellular production of cytokines in CD8<sup>+</sup> T cells from immunized mice (mean  $\pm$  SD, n = 3). FIG. 2D, graphs plotting *in vivo* cytolytic activity in immunized mice. OVA-peptide or control-peptide pulsed target cells (syngeneic splenocytes) were labeled with high or low dose CFSE (5  $\mu$ M for OVA-peptide pulsed cells; 0.5  $\mu$ M for control-peptide pulsed cells) and mixed (1:1, 2.5  $\times$  10<sup>6</sup> of each) and injected i.v. into WT or B7-H1-deficient mice. Histogram plots (left) show the percentage of remaining target cells in the spleen 4 hours after target cell transfer. Bar graph (right) shows percentage of specific lysis in the spleen (mean  $\pm$  SD, n = 3).

FIGS. 3A and 3B contain FACS scans and graphs showing enhanced memory CD8<sup>+</sup> T-cell recall responses and improved antitumor immunity in the lung in the absence of B7-H1. On day 35 after immunization, immunized or naive WT and B7-H1-deficient mice were injected (i.v.) with 5  $\times$  10<sup>5</sup> B16-OVA tumor cells. FIG. 3A, percentage and absolute numbers of IFN $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells in the lung of immunized mice (mean  $\pm$  SD, n = 3) on day 4 after tumor injection. \*p < 0.01 compared with WT mice. FIG. 3B, metastatic tumor foci in the lung tissue were identified and counted on day 20 after tumor injection (mean  $\pm$  SD, n = 5). N.S.: not significant.

FIGS. 4A-4D contain a series of FACS scans and a graph showing that CD11a<sup>high</sup> CD8<sup>+</sup> T cells represent antigen-primed effector T cells. Spleen cells from naive or immunized WT and B7-H1-deficient mice were analyzed by co-staining with anti-CD11a and K<sup>b</sup>/OVA tetramer or functional markers. FIG. 4A, FACS scans showing the percentage of CD11a<sup>high</sup> CD8<sup>+</sup> T cells from WT and B7-H1-deficient immunized mice. FIG. 4B, graph plotting average percentage of CD11a<sup>high</sup> CD8<sup>+</sup> T cells from WT and B7-H1-deficient immunized mice (mean  $\pm$  SD, n = 4). FIG. 4C, FACS scans showing the percentage of antigen-specific tetramer<sup>+</sup> (K<sup>b</sup>/OVA-tet) cells in CD11a<sup>high</sup> and CD11a<sup>low</sup> CD8<sup>+</sup> T-cell population. FIG. 4D, FACS scans showing CTL functional assay of CD11a<sup>high</sup> and CD11a<sup>low</sup> CD8<sup>+</sup> T cells after a brief re-stimulation *in vitro*. Degranulation of CTLs was analyzed by CD107a mobilization, followed by intracellular staining for IPN $\gamma$ . Numbers indicate percentages of gated areas.

FIGS. 5A-5D contain a series of FACS scans and a graph showing fewer apoptotic antigen-primed CD8<sup>+</sup> T cells in B7-H1-deficient mice. On day 7 after immunization, spleen cells were analyzed for proliferation and apoptosis. FIGS. 5A and 5B, FACS scans showing Ki67 expression and BrdU incorporation, respectively, analyzed in CD11a<sup>high</sup> or CD11a<sup>low</sup> CD8<sup>+</sup> T cells. Numbers are percentages of gated area in total CD8<sup>+</sup> T cells. FIG. 5C, FACS scans of TMRE<sup>low</sup> Annexin V<sup>+</sup> apoptotic cells measured in CD11a<sup>high</sup> and CD11a<sup>low</sup> CD8<sup>+</sup> T cells. FIG. 5D, graph plotting the percentage of apoptotic cells (TMRE<sup>low</sup> Annexin V<sup>+</sup>) in CD11a<sup>high</sup> CD8<sup>+</sup> T cells (mean  $\pm$  SD, n = 4).

FIGS. 6A-6D contain a series of histograms and a graph showing lower Bim levels in antigen-primed CD8<sup>+</sup> T cells in B7-H1-deficient mice. FIG. 6A, flow cytometry assay of the intracellular expression of Bim, Bcl-2 and Bcl-xL in gated CD11a<sup>high</sup> CD8<sup>+</sup> T cells in the spleen of WT (red) and B7-H1-deficient (blue) mice on day 7 after immunization. Numbers are mean fluorescence intensity (MFI) of Bim expression. FIG. 6B, graph showing average MFI of Bim expressed by CD11a<sup>high</sup> CD8<sup>+</sup> T cells (mean  $\pm$  SD, n = 9). FIG. 6C, intracellular expression of Bim in CD11a<sup>high</sup> CD8<sup>+</sup> T cells in the liver of immunized mice. Numbers are MFI. FIG. 6D, Bim expression in total CD8<sup>+</sup> T cells in the spleen of naive WT (red) and B7-H1-deficient (blue) mice.

FIG. 7 contains a series of histograms showing the extrinsic role of B7-H1 in regulation of Bim. WT OT-1 CD8<sup>+</sup> T cells (Thy1.1<sup>+</sup>) were transferred in WT (red) or B7-H1-deficient (blue) host mice one day before immunization with OVA plus poly I:C. On day 7 after immunization, the OT-1 CD8<sup>+</sup> T cells in the spleen and liver were identified by the Thy1.1 marker and analyzed for intracellular expression of Bim. Numbers are MFI.

FIGS. 8A-8F show that B7-H1 co-stimulation induces upregulation of Bim protein levels in activated T cells. Pre-activated CD8<sup>+</sup> T cells were incubated with platebound B7-H1 or control fusion protein (Fc) for 48 hours in the

presence of anti-CD3. FIG. 8A, Western blot showing Bim isoform expression in CD8+ T cells. FIG. 8B, histogram showing expression of total Bim in CD8+ T cells co-stimulated with B7-H1 (blue) or control protein (red). Numbers are MFI. FIG. 8C, graph plotting average MFI of Bim expressed by activated CD8+ T cells (mean  $\pm$  SD, n = 5). FIG. 8D, graph plotting the percentage of live (trypan blue exclusive) CD8+ T cells in culture (mean  $\pm$  SD, n = 5). FIG. 8E, FACS scans indicating apoptosis of CD8+ T cells isolated from WT, Bim-deficient, and Bcl-2 transgenic (Tg) mice. Numbers show percentage of TMRE<sup>low</sup> Annexin V+ apoptotic T cells in total CD8+ T cells. FIG. 8F, graph plotting average MFI of Bim expressed by CD8+ T cells in culture with anti-B7-H1 Ab (10B5, blocking B7-H1 binding to both PD-1 and CD80; 43H12, blocking B7-H1 binding to CD80 only), anti-PD-1 Ab (G4), or control Ab (10  $\mu$ g/mL of each) (mean  $\pm$  SD, n = 3).

FIGS. 9A-9C contain a series of plots showing that B7-H1 co-stimulation inhibits activation of Akt. Pre-activated CD8+ T cells were stimulated with plate-bound B7-H1 or control fusion protein (Fc). After 24 hours of stimulation, CD8+ T cells were harvested and used for analysis. FIG. 9A, graph plotting analysis of *Bcl2l1* transcript levels by real-time qPCR using the comparative CT method. GAPDH served as the internal control gene. Graph shows fold change (mean  $\pm$  SD, n = 4). FIG. 9B, histograms plotting phosphorylation of Akt (left) and mTOR (right), analyzed by intracellular staining of CD8+ T cells with anti-phospho-Akt and anti-phospho-mTOR Abs. Numbers show percentage of positive stained cells. FIG. 9C, bar graph plotting average MFI of phospho-Akt and phospho-mTOR expression (mean  $\pm$  SD, n = 3). N.S.: not significant.

FIG. 10 contains representative nucleic acid (top) and amino acid (bottom) sequences for human B7-H1 (SEQ ID NOS:1 and 2, respectively).

FIG. 11 contains representative nucleic acid (top) and amino acid (bottom) sequences for human PD-1 (SEQ ID NOS:3 and 4, respectively).

FIGS. 12A and 12B contain representative nucleic acid (12A) and amino acid (12B) sequences for human CD80 (SEQ ID NOS:5 and 6, respectively).

FIG. 13 contains a plot (left) showing the identification of CD8+ T cells based on their expression of CD11a<sup>high</sup> and PD-1+ (left panel). Lymphocytes were stained with CD8, CD11a and PD-1, followed by intracellular staining for Bim. FIG. 13 also contains a histogram plotting expression of Bim by subsets of CD8+ T cells (Tn: T naive cells; PD-1- , PD-1 negative primed cells; PD-1 +, PD-1 positive primed cells). Only the PD-1+ primed cells CD8+ T cells expressed high levels of Bim.

FIG. 14 is a pair of graphs plotting the level of Bim expression in tumor-reactive PD-1+ CD11a<sup>high</sup> CD8+ T cells in the peripheral blood of 26 melanoma patients as compared to 11 normal, healthy controls (left panel, P=0.007 by unpaired Student T test), and in tumor-reactive PD-1+ CD11a<sup>high</sup> CD8+ T cells in the peripheral blood of 11 prostate cancer patients as compared to 11 normal, healthy controls (right panel, P=0.001 by unpaired Student T test).

FIG. 15 is a pair of graphs plotting Bim expression in PD-1 negative (PD-1-) and PD-1 positive (PD-1+) CD11a<sup>high</sup> CD8+ T cells from melanoma patients (left) and healthy controls (right). Bim was significantly increased in the PD-1+ populations (p=0.0081) in melanoma patients.

FIG. 16 is a pair of graphs plotting the level of Bim expression in tumor-reactive PD-1+ CD11a<sup>high</sup> CD8+ T cells in the peripheral blood of 26 melanoma patients as compared to 11 normal, healthy controls (left panel, indicating "Bim low" and "Bim high" samples), and plotting the survival rate for "Bim low" vs. "Bim high" patients (right panel).

FIG. 17A is a pair of graphs showing that B7-H1 protein induced expression of Bim in human pre-activated CD8+ T cells. FIG. 17B is a picture of a Western blot showing Bim levels in the cells.

FIG. 18 is a pair of graphs showing that an anti-PD-1 antibody significantly blocked B7-H1-induced Bim up-regulation in a dose dependent fashion (left panel), and that the blocking effects of the anti-PD-1 antibody were inversely correlated with the higher levels of Bim induced by B7-H1 (right panel).

FIG. 19 is a pair of graphs showing that the frequency of Bim+PD-1+ CD8 T cells was significantly higher in the peripheral blood of melanoma patients before treatment than in a healthy control group (left panel), and that after anti-PD-1 antibody therapy, about 67% of the melanoma patients demonstrated a significant reduction in the frequency of Bim+PD-1+ CD8 T cells (right panel).

FIG. 20 is a pair of graphs showing that B7-H1 expressed by tumor cells induced Bim up-regulation in human pre-activated CD8 T cells.

FIG. 21 is a pair of photographs (left) and a graph (right) showing that Bim expression was associated with B7-H1 expression in human renal cell carcinoma (RCC). In particular, the graph in the right panel shows that Bim+ tumor infiltrating lymphocytes (TILs) were increased in B7-H1 positive tumor tissues. Bim reactivity scores: 0, absence; 1, focal; 2, moderate; 3, marked. Contingency analysis using Fisher's exact test (p<0.01).

FIG. 22 is a pair of graphs showing that Bim expression was correlated with Granzyme B and T-bet (a transcription factor of effector T cells) expressed by cancer-related PD-1+ CD11a<sup>high</sup> CD8+ T cells, suggesting that Bim expression is associated with effector CD8+ T cell differentiation.

FIG. 23 is a pair of graphs showing that Bim expression declined in PD-1+ CD11a<sup>high</sup> CD8 T cells following radio-therapy in some melanoma (left panel) and prostate (right panel) cancer patients.

## DETAILED DESCRIPTION

**[0013]** This document provides materials and methods for identifying patients as being more likely to benefit from checkpoint blockade therapy, materials and methods for determining optimal therapeutic timing and dosing schedules, and methods and materials for treating cancer. For example, this document provides methods and materials for identifying a mammal (e.g., a human) as having an elevated level of Bim, and treating the mammal with a molecule that can interfere with the interaction between B7-H1 and PD-1, and/or the interaction between B7-H1 and CD80 (e.g., an antibody against B7-H1, PD-1, or CD80, or with a fusion protein containing a portion of PD-1 or a portion of CD80 fused to an immunoglobulin (Ig) Fc domain). As described herein, elevated levels of Bim can be related to increased apoptosis of antigen-primed CD8<sup>+</sup> T cells, but inhibiting the interaction of B7-H1 with PD-1 or CD80 can lead to reduced levels of Bim and reduced T cell apoptosis.

**[0014]** The term "elevated level" as used herein with respect to a level of Bim refers to a level that is greater (e.g., 50% greater, 2-fold greater, 3-fold greater, or more than 3-fold greater) than a reference level of Bim. The term "reference level" as used herein with respect to Bim refers to the level of Bim typically observed in healthy mammals without cancer. For example, a reference level of Bim can be the average level of Bim present in samples obtained from a random sampling of 50 humans free of cancer.

**[0015]** The presence of an elevated level of Bim can be determined by measuring, for example, protein levels or nucleic acid levels. For example, the level of Bim protein can be measured in a sample of blood (e.g., a peripheral blood sample) or another bodily fluid from a mammal with cancer or from a control mammal, using cell staining, western blotting, or other immunological techniques. The level of Bim expression also can be measured at the nucleic acid level, using Northern blotting, or any other method suitable for determining mRNA levels of *Bcl2l1*, which encodes the Bim protein. In some cases, Bim protein or nucleic acid levels can be measured in tumor tissue samples, ascites samples, or lymphoid organ samples. It will be appreciated that levels from comparable samples are used when determining whether or not a particular level is an elevated level.

**[0016]** A representative example of a human B7-H1 nucleic acid has the sequence set forth in GENBANK® Accession No. AF177937 (GI No. 6708118) (SEQ ID NO:1; Figure 10), and a representative human B7-H1 polypeptide has the sequence set forth in GENBANK® Accession No. AAF25807 (GI No. 6708119) (SEQ ID NO:2; Figure 10).

**[0017]** A representative example of a human PD-1 nucleic acid can have the sequence set forth in GENBANK® Accession No. BC074740.2 (GI No. 50960296) (SEQ ID NO:3; Figure 11), and representative example of a human PD-1 polypeptide has the sequence set forth in GENBANK® Accession No. AAH74740.1 (GI No. 49902307) (SEQ ID NO:4; Figure 11).

**[0018]** A representative example of a human CD80 nucleic acid has the sequence set forth in NCBI Reference No. NM\_005191.3 (GI No. 113722122) (SEQ ID NO:5; Figure 12A), and a representative example of a human CD80 polypeptide has the sequence set forth in NCBI Reference No. NP\_005182.1 (GI No. 4885123) (SEQ ID NO:6; Figure 12B).

**[0019]** Once the level of Bim within a sample from a mammal is determined, the level can be compared to a reference level and used to classify the mammal as having or lacking an elevated level of Bim.

**[0020]** Once a mammal has been identified as having an elevated level of Bim as described herein, the mammal can be administered a molecule that inhibits the interaction between B7-H1 and PD-1 and/or the interaction between B7-H1 and CD80. Examples of such molecules include, without limitation, antibodies (e.g., anti-B7-H1 antibodies, anti-PD-1 antibodies, or anti-CD80 antibodies), and fusion proteins (e.g., PD-1 fusion proteins or CD80 fusion proteins). Such fusion proteins can contain, for example, the extracellular domain of PD-1 fused to an IgG Fc domain, or the extracellular domain of CD80 fused to an IgG Fc domain. After administration, the antibody/ies or fusion protein(s) can bind B7-H1, thus reducing or blocking B7-H1's action in inducing Bim up regulation.

**[0021]** The term "antibody" includes monoclonal antibodies, polyclonal antibodies, recombinant antibodies, humanized antibodies (Jones et al. (1986) *Nature* 321:522-525; Riechmann et al. (1988) *Nature* 332:323-329; and Presta (1992) *Curr. Op. Struct. Biol.* 2:593-596), chimeric antibodies (Morrison et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855), multispecific antibodies (e.g., bispecific antibodies) formed from at least two antibodies, and antibody fragments. The term "antibody fragment" comprises any portion of the afore-mentioned antibodies, such as their antigen binding or variable regions. Examples of antibody fragments include Fab fragments, Fab' fragments, F(ab')<sub>2</sub> fragments, Fv fragments, diabodies (Hollinger et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448), single chain antibody molecules (Plückthun in: *The Pharmacology of Monoclonal Antibodies* 113, Rosenberg and Moore, eds., Springer Verlag, N.Y. (1994), 269-315) and other fragments as long as they exhibit the desired capability of binding to B7-H1, PD-1, or CD80.

**[0022]** Examples of anti-human B7-H1 antibodies include, without limitation, anti-human B7-H1 antibodies commercially available from Biolegend (e.g., Catalog No. 329701 or 329702; San Diego, CA) or eBioscience (e.g., Catalog No. 14-5983-80 or 14-5983-82).

**[0023]** Examples of anti-human PD-1 antibodies include, without limitation, anti-human PD-1 antibodies commercially available from Biolegend (e.g., Catalog No. 329904 or 329905) or eBioscience (Catalog No. 12-2799-42; San Diego, CA).

**[0024]** Examples of anti-human CD80 antibodies include, without limitation, anti-human CD8 antibodies commercially

available from Biolegend (e.g., Catalog No. 305201 or 305202) or eBioscience (e.g., Catalog No. 14-0809-80 or 14-0809-82).

**[0025]** The term "antibody," as used herein, also includes antibody-like molecules that contain engineered sub-domains of antibodies or naturally occurring antibody variants. These antibody-like molecules may be single-domain antibodies such as V<sub>H</sub>-only or V<sub>L</sub>-only domains derived either from natural sources such as camelids (Muyldermans et al. (2001) Rev. Mol. Biotechnol. 74:277-302) or through *in vitro* display of libraries from humans, camelids or other species (Holt et al. (2003) Trends Biotechnol. 21:484-90). In certain embodiments, the polypeptide structure of the antigen binding proteins can be based on antibodies, including, but not limited to, minibodies, synthetic antibodies (sometimes referred to as "antibody mimetics"), human antibodies, antibody fusions (sometimes referred to as "antibody conjugates"), and fragments thereof, respectively.

**[0026]** An "Fv fragment" is the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy chain variable domain and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three CDR's of each variable domain interact to define an antigen-binding site on the surface of the V<sub>H</sub>-V<sub>L</sub> dimer. Collectively, the six CDR's confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDR's specific for an antigen) has the ability to recognize and bind the antigen, although usually at a lower affinity than the entire binding site. The "Fab fragment" also contains the constant domain of the light chain and the first constant domain (C<sub>H1</sub>) of the heavy chain. The "Fab fragment" differs from the "Fab' fragment" by the addition of a few residues at the carboxy terminus of the heavy chain C<sub>H1</sub> domain, including one or more cysteines from the antibody hinge region. The "F(ab')<sub>2</sub> fragment" originally is produced as a pair of "Fab' fragments" which have hinge cysteines between them. Methods of preparing such antibody fragments, such as papain or pepsin digestion, are known to those skilled in the art.

**[0027]** An antibody can be of the IgA-, IgD-, IgE, IgG- or IgM-type, including IgG- or IgM-types such as, without limitation, IgG1-, IgG2-, IgG3-, IgG4-, IgM1- and IgM2-types. For example, in some cases, the antibody is of the IgG1-, IgG2- or IgG4- type.

**[0028]** In some embodiments, antibodies as used in the methods described herein can be fully human or humanized antibodies. Human antibodies can avoid certain problems associated with xenogeneic antibodies, such as antibodies that possess murine or rat variable and/or constant regions. First, because the effector portion is human, it can interact better with other parts of the human immune system, e.g., to destroy target cells more efficiently by complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. Second, the human immune system should not recognize the antibody as foreign. Third, half-life in human circulation will be similar to naturally occurring human antibodies, allowing smaller and less frequent doses to be given. Methods for preparing human antibodies are known in the art.

**[0029]** In addition to human antibodies, "humanized" antibodies can have many advantages. Humanized antibodies generally are chimeric or mutant monoclonal antibodies from mouse, rat, hamster, rabbit or other species, bearing human constant and/or variable region domains or specific changes. Techniques for generating humanized antibodies are well known to those of skill in the art. For example, controlled rearrangement of antibody domains joined through protein disulfide bonds to form new, artificial protein molecules or "chimeric" antibodies can be utilized (Konieczny et al. (1981) Haematologia (Budap.) 14:95). Recombinant DNA technology can be used to construct gene fusions between DNA sequences encoding mouse antibody variable light and heavy chain domains and human antibody light and heavy chain constant domains (Morrison et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851).

**[0030]** DNA sequences encoding antigen binding portions or complementarity determining regions (CDR's) of murine monoclonal antibodies can be grafted by molecular means into DNA sequences encoding frameworks of human antibody heavy and light chains (Jones et al. (1986) Nature 321:522; Riechmann et al. (1988) Nature 332:323). Expressed recombinant products are called "reshaped" or humanized antibodies, and comprise the framework of a human antibody light or heavy chain and antigen recognition portions, CDR's, of a murine monoclonal antibody.

**[0031]** Other methods for designing heavy and light chains and for producing humanized antibodies are described in, for example, U.S. Patent Nos. 5,530,101; 5,565,332; 5,585,089; 5,639,641; 5,693,761; 5,693,762; and 5,733,743. Yet additional methods for humanizing antibodies are described in U.S. Patent Nos. 4,816,567; 4,935,496; 5,502,167; 5,558,864; 5,693,493; 5,698,417; 5,705,154; 5,750,078; and 5,770,403, for example.

**[0032]** Molecules that interfere with the interaction between B7-H1 and PD-1, and/or the interaction between B7-H1 and CD80, as described herein (e.g., antibodies against B7-H1, PD-1, and CD80, as well as fusion proteins containing portions of PD-1 or CD80 linked to an Ig Fc domain), can be incorporated into pharmaceutical compositions for treatment of cancer. Thus, this document also provides the use of such molecules in the manufacture of medicaments for treating cancer. The compositions can further include one or more pharmaceutically acceptable carriers, diluents and/or adjuvants. The potency of the pharmaceutical compositions provided herein typically is based on the binding of the antibody or fusion protein to B7-H1.

**[0033]** A "pharmaceutically acceptable carrier" (also referred to as an "excipient" or a "carrier") is a pharmaceutically acceptable solvent, suspending agent, stabilizing agent, or any other pharmacologically inert vehicle for delivering one or more therapeutic compounds to a subject, which is nontoxic to the cell or mammal being exposed thereto at the

dosages and concentrations employed. Pharmaceutically acceptable carriers can be liquid or solid, and can be selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, and other pertinent transport and chemical properties, when combined with one or more of therapeutic compounds and any other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers that do not deleteriously react with amino acids include, by way of example and not limitation: water, saline solution, binding agents (e.g., polyvinylpyrrolidone or hydroxypropyl methylcellulose), fillers (e.g., lactose and other sugars, gelatin, or calcium sulfate), lubricants (e.g., starch, polyethylene glycol, or sodium acetate), disintegrates (e.g., starch or sodium starch glycolate), and wetting agents (e.g., sodium lauryl sulfate). Pharmaceutically acceptable carriers also include aqueous pH buffered solutions or liposomes (small vesicles composed of various types of lipids, phospholipids and/or surfactants which are useful for delivery of a drug to a mammal). Further examples of pharmaceutically acceptable carriers include buffers such as phosphate, citrate, and other organic acids, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine, monosaccharides, disaccharides, and other carbohydrates including glucose, mannose or dextrans, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, salt-forming counterions such as sodium, and/or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

**[0034]** Pharmaceutical compositions can be formulated by mixing one or more active agents with one or more physiologically acceptable carriers, diluents, and/or adjuvants, and optionally other agents that are usually incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A pharmaceutical composition can be formulated, e.g., in lyophilized formulations, aqueous solutions, dispersions, or solid preparations, such as tablets, dragees or capsules. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences (18th ed, Mack Publishing Company, Easton, PA (1990)), particularly Chapter 87 by Block, Lawrence, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies as described herein, provided that the active agent in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. See, also, Baldrick (2000) Regul. Toxicol. Pharmacol. 32:210-218; Wang (2000) Int. J. Pharm. 203:1-60; Charman (2000) J. Pharm. Sci. 89:967-978; and Powell et al. (1998) PDA J. Pharm. Sci. Technol. 52:238-311), and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.

**[0035]** Pharmaceutical compositions include, without limitation, solutions, emulsions, aqueous suspensions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, for example, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other; in general, emulsions are either of the water-in-oil (w/o) or oil-in-water (o/w) variety. Emulsion formulations have been widely used for oral delivery of therapeutics due to their ease of formulation and efficacy of solubilization, absorption, and bioavailability.

**[0036]** Compositions and formulations can include sterile aqueous solutions, which also can contain buffers, diluents and other suitable additives (e.g., penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers). Compositions additionally can contain other adjunct components conventionally found in pharmaceutical compositions. Thus, the compositions also can include compatible, pharmaceutically active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or additional materials useful in physically formulating various dosage forms of the compositions provided herein, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. Furthermore, the composition can be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings, and aromatic substances. When added, however, such materials should not unduly interfere with the biological activities of the polypeptide components within the compositions provided herein. The formulations can be sterilized if desired.

**[0037]** In some embodiments, a composition containing an antibody or fusion protein as provided herein (e.g., an anti-B7-H7, anti-PD-1, or anti-CD80 antibody, or a PD-1 FC or CD80 Fc fusion protein) can be in the form of a solution or powder with or without a diluent to make an injectable suspension. The composition may contain additional ingredients including, without limitation, pharmaceutically acceptable vehicles, such as saline, water, lactic acid, mannitol, or combinations thereof, for example.

**[0038]** Any appropriate method can be used to administer a molecule as described herein to a mammal. Administration can be, for example, parenteral (e.g., by subcutaneous, intrathecal, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous drip). Administration can be rapid (e.g., by injection) or can occur over a period of time (e.g., by slow infusion or administration of slow release formulations). In some embodiments, administration can be topical (e.g., transdermal, sublingual, ophthalmic, or intranasal), pulmonary (e.g., by inhalation or insufflation of powders or

aerosols), or oral. In addition, a composition containing an antibody or fusion protein as described herein can be administered prior to, after, or in lieu of surgical resection of a tumor.

**[0039]** A composition containing an antibody (e.g., an anti-B7-H1 antibody, anti-PD-1 antibody, or anti-CD80 antibody) or a fusion protein (e.g., a PD-1 Fc fusion or a CD80 Fc fusion) can be administered to a mammal in any appropriate amount, at any appropriate frequency, and for any appropriate duration effective to achieve a desired outcome (e.g., to increase progression-free survival). In some cases, a composition containing an antibody or fusion protein as described herein can be administered to a mammal having cancer to reduce the progression rate of the cancer by 5, 10, 25, 50, 75, 100, or more percent. For example, the progression rate can be reduced such that no additional cancer progression is detected. Any appropriate method can be used to determine whether or not the progression rate of cancer is reduced. For skin cancer (e.g., melanoma), for example, the progression rate can be assessed by imaging tissue at different time points and determining the amount of cancer cells present. The amounts of cancer cells determined within tissue at different times can be compared to determine the progression rate. After treatment as described herein, the progression rate can be determined again over another time interval. In some cases, the stage of cancer after treatment can be determined and compared to the stage before treatment to determine whether or not the progression rate has been reduced.

**[0040]** In some cases, a composition containing an antibody or a fusion protein as described herein can be administered to a mammal having cancer under conditions where progression-free survival is increased (e.g., by 5, 10, 25, 50, 75, 100, or more percent) as compared to the median progression-free survival of corresponding mammals having untreated cancer or the median progression-free survival of corresponding mammals having cancer and treated with other therapies (e.g., chemotherapeutic agents). Progression-free survival can be measured over any length of time (e.g., one month, two months, three months, four months, five months, six months, or longer).

**[0041]** Administration to a mammal of a molecule as set forth herein can result in increased numbers of naturally-occurring tumor-reactive CD8<sup>+</sup> T cells, which can exert anti-cancer effects against cancer cells present within the mammal.

**[0042]** An effective amount of a composition containing a molecule as provided herein can be any amount that reduces the progression rate of cancer, increases the progression-free survival rate, or increases the median time to progression without producing significant toxicity to the mammal. Optimum dosages can vary depending on the relative potency of individual polypeptides (e.g., antibodies and fusion proteins), and can generally be estimated based on EC<sub>50</sub> found to be effective in in vitro and in vivo animal models. Typically, dosage is from 0.01 µg to 100 g per kg of body weight. For example, an effective amount of an antibody or fusion protein can be from about 1 mg/kg to about 100 mg/kg (e.g., about 5 mg/kg, about 10 mg/kg, about 20 mg/kg, about 50 mg/kg, or about 75 mg/kg). If a particular mammal fails to respond to a particular amount, then the amount of the antibody or fusion protein can be increased by, for example, two fold. After receiving this higher concentration, the mammal can be monitored for both responsiveness to the treatment and toxicity symptoms, and adjustments made accordingly. The effective amount can remain constant or can be adjusted as a sliding scale or variable dose depending on the mammal's response to treatment. Various factors can influence the actual effective amount used for a particular application. For example, the frequency of administration, duration of treatment, use of multiple treatment agents, route of administration, and severity of the cancer may require an increase or decrease in the actual effective amount administered.

**[0043]** The frequency of administration can be any frequency that reduces the progression rate of cancer, increases the progression-free survival rate, or increases the median time to progression without producing significant toxicity to the mammal. For example, the frequency of administration can be once or more daily, biweekly, weekly, monthly, or even less. The frequency of administration can remain constant or can be variable during the duration of treatment. A course of treatment can include rest periods. For example, a composition containing an antibody or fusion protein as provided herein can be administered over a two week period followed by a two week rest period, and such a regimen can be repeated multiple times. As with the effective amount, various factors can influence the actual frequency of administration used for a particular application. For example, the effective amount, duration of treatment, use of multiple treatment agents, route of administration, and severity of the cancer may require an increase or decrease in administration frequency.

**[0044]** An effective duration for administering a composition provided herein can be any duration that reduces the progression rate of cancer, increases the progression-free survival rate, or increases the median time to progression without producing significant toxicity to the mammal. Thus, the effective duration can vary from several days to several weeks, months, or years. In general, the effective duration for the treatment of cancer can range in duration from several weeks to several months. In some cases, an effective duration can be for as long as an individual mammal is alive. Multiple factors can influence the actual effective duration used for a particular treatment. For example, an effective duration can vary with the frequency of administration, effective amount, use of multiple treatment agents, route of administration, and severity of the cancer.

**[0045]** After administering a composition provided herein to a mammal, the mammal can be monitored to determine whether or not the cancer was treated. For example, a mammal can be assessed after treatment to determine whether

or not the progression rate of the cancer has been reduced (e.g., stopped). Any method, including those that are standard in the art, can be used to assess progression and survival rates.

**[0046]** The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

## EXAMPLES

### Example 1 - Materials and Methods

**[0047]** *Mice, cell lines and reagents:* Female CD45.2+ C57BL/6 mice were purchased from Taconic Farms and CD45.1+ congenic C57BL/6-Ly5.1 mice were purchased from National Cancer Institute. OT-1 TCR (Thy 1.1+) transgenic mice were provided by T. Tian (Harvard University, Boston, MA). B7-H1-deficient C57BL/6 mice were provided by L. Chen (Yale University, New Haven, CT; Dong et al., Immunity 20:327-336, 2004). *Bcl211*<sup>-/-</sup> mice and *Cd80*<sup>-/-</sup> mice were purchased from Jackson Laboratory. *Cd80*<sup>-/-</sup> mice were crossbred into WT OT-1 mice and produced *Cd80*<sup>-/-</sup> OT-1 mice. *Bcl-2* transgenic mice were provided by V. Shapiro (Mayo Clinic, Rochester). Mice were maintained under pathogen-free conditions and used at 8-12 weeks of age. B16-OVA murine melanoma cells were provided by R. Vile (Mayo Clinic, Rochester, MN), and were cultured in RPMI 1640 medium (Cellgro) with 10% FBS (Life Technologies), 1 U/mL penicillin, 1 µg/mL streptomycin and 20 mM HEPES buffer (all from Mediatech). Hamster anti-mouse B7-H1 mAb (10B5) and PD-1 (G4) was obtained from hybridoma cells provided by L. Chen. Hamster anti-mouse B7-H1 mAb (43H12) was provided by K. Tamada (John Hopkins University).

**[0048]** *Flow cytometry analysis:* Class I MHC (K<sup>b</sup>OVA peptide SIINFEKL; SEQ ID NO:1) tetramer and negative control tetramer were purchased from Beckman Coulter. Fluorochrome-conjugated Abs against CD8, CD11a, Fas (CD95), Fas ligand, CD90.1 (Thy 1.1), CD90.2 (Thy 1.2), CD107a, IPN<sub>γ</sub>, IL-2 and TNF $\alpha$  were purchased from BD Biosciences, BioLegend, or eBiosciences. To detect intracellular cytokine levels, cells were incubated with GolgiPlug (BD Biosciences) for 4 hours prior to analysis. Cells were stained for surface antigens, and then incubated in Fixation Buffer (BioLegend) for 20 minutes at room temperature, followed by permeabilization in Permeabilization Wash Buffer (BioLegend). Fixed and permeabilized cells were then stained with Abs for 20 minutes at room temperature. Abs to Akt, Bcl-xL, Bcl-2, Bim and mTOR and fluorochrome-conjugated secondary Abs were purchased from Cell Signaling (Danvers, MA). To detect intracellular levels of Akt, Bcl-xL, Bcl-2, Bim and mTOR, T cells were first stained for surface antigens, then fixed with 2% paraformaldehyde for 10 minutes at 37°C, followed by permeabilization with ice-cold methanol for 30 minutes. After blocking with 15% rat serum for 15 minutes, cells were stained with Abs for 1 hour at room temperature. After staining, cells were washed three times with incubation buffer before analysis. At least 100,000 viable cells were live gated on FACScan or FACSCalibur (BD Biosciences) instrumentation. Flow cytometry analysis was performed using FlowJo software (Tree Star).

**[0049]** *T-cell immunization, activation, apoptosis assay and proliferation assay:* Mice were immunized by i.p. injection of 0.5 mg ovalbumin (OVA, from Sigma-Aldrich) and 50 µg poly (I:C) (Sigma Aldrich). For *in vitro* T-cell activation and apoptosis assay, purified CD8+ T cells were labeled with CFSE (Invitrogen-Molecular Probes) and incubated with OVA peptide<sub>257-264</sub> (Mayo Clinic Core Facilities) at 0.2 µg/mL for 72 hours. Apoptosis of CD8+ T cells was analyzed by staining using Annexin V (BD Biosciences) and TMRE (tetramethylrhodamine ethyl ester, Invitrogen/Molecular Probes T-669). Proliferation was also measured by detection of BrdU incorporation and Ki67 staining. Immunized mice were injected i.p. with 0.8 mg/mL BrdU (BD Biosciences) on days 4 through 6 following immunization. On day 7 after immunization BrdU incorporation was determined by intra-nuclear staining with anti-BrdU (B9285, Sigma-Aldrich) and anti-Ki67 (556027, BD Biosciences).

**[0050]** *In vivo CTL assay.* For the *in vivo* CTL assay, OVA<sub>257-264</sub> peptide-pulsed or control peptide-pulsed spleen cells (as target cells) from syngeneic mice were labeled with a high dose of CFSE (5 µM) or low dose of CFSE (0.5 µM), mixed at 1:1 (2.5 × 10<sup>6</sup> of each) before injection. Target cells were i.v. injected into immunized mice on day 4 after re-challenge with cognate antigen protein. The CTL activity was determined 4 hours after target cell transfer. Specific lysis is calculated using the following formulas:

$$\text{ratio} = (\% \text{ CFSE}_{\text{high}} / \% \text{ CFSE}_{\text{low}}), \% \text{ specific lysis} = [1 - (\text{ratio}_{\text{primed}} / \text{ratio}_{\text{unprimed}})] \times 100\%.$$

**[0051]** *Tumor studies:* Mice were inoculated i.v. with 5 × 10<sup>5</sup> B16-OVA tumor cells on day 25 after immunization. On day 21-post tumor injection, mice were sacrificed and the lung tissue was perfused with PBS. The number of tumor foci on the lung tissue was counted.

**[0052]** *T-cell transfer experiments:* Purified CD8+ T cells (1 × 10<sup>6</sup>) from Thy1.1+ OT-1 transgenic mice were i.v. injected into Thy 1.2+ WT or B7-H1-deficient recipient mice, followed by immunization with OVA plus poly I:C. On day

7 after immunization, transferred CD8<sup>+</sup> T cells were identified by their expression of Thy1.1 and used for detection of intracellular expression of Bim, Bcl-2 and Bcl-xL. Equal numbers of Cd80<sup>-/-</sup> (CD45.2<sup>+</sup>) and WT OT-1 (Thy1.1<sup>+</sup>, CD45.2<sup>+</sup>) CD8<sup>+</sup> T cells ( $10^6$  of each) were i.v. injected into CD45.1<sup>+</sup> mice followed with immunization of OVA and poly I:C. The transferred OT-1 CD8<sup>+</sup> T cells in the spleen were identified by flow cytometry.

**[0053]** *In vitro* T-cell activation and culturing with fusion proteins: Spleen cells were harvested from naive mice and pre-activated with ConA (5 µg/mL, L7647, Sigma-Aldrich) for 48 hours. Following activation, CD8<sup>+</sup> T cells were purified (EasySep CD8<sup>+</sup> T-cell negative selection kit, Stem Cell Technologies) and incubated with plate-bound anti-CD3 (BD Biosciences) and B7-H1 Fc fusion protein or control Fc protein (R&D Systems). Cultures were maintained for indicated time periods, and then cells were harvested for analysis.

**[0054]** *Western blotting*: Cells were lysed with NETN buffer (0.5% NP40, 150 mM NaCl, 50 mM Tris and 1 mM EDTA). Cell lysates were boiled and run on SDS-PAGE gels (BioRad), transferred to nitrocellulose membrane (Millipore), and blotted using standard procedures.

**[0055]** *Quantitative RT-PCR*: Total RNA was isolated from purified CD8<sup>+</sup> T cells (RNeasy Kit, Qiagen), and reverse transcribed (iScriptcDNA synthesis kit, BioRad). Samples were analyzed for Bim transcript levels using Bcl211 primers (Qiagen) and QuantiFast SYBR Green PCR Master Mix (Qiagen) on an iCycler (BioRad). GAPDH levels were used to normalize data by the comparative CT method.

**[0056]** *Statistical analysis*: A two-sided, unpaired or paired Student's t-test was used to assess statistical differences in experimental groups. A p value < 0.05 was considered statistically significant.

#### Example 2 - More memory T cells are generated in the absence of B7-H1

**[0057]** The kinetics of CD8<sup>+</sup> T-cell responses in the spleen and liver of WT and B7-H1-deficient C57BL/6 mice were compared following immunization with ovalbumin (OVA) protein and polyinosinic:polycytidylic acid (poly I:C)) as adjuvant. An increased number of CD8<sup>+</sup> T cells was observed at the peak of the immune response (day 7-post immunization) in the spleen and liver of B7-H1-deficient mice as compared with WT mice. During the contraction phase (days 7 to 14 post-immunization), there was a significant delay in the reduction of antigen-specific CD8<sup>+</sup> T cells in the spleen and liver of B7-H1-deficient mice as compared with WT mice. On day 40 following immunization, more antigen-specific memory CD8<sup>+</sup> T cells were detected in B7-H1-deficient mice as compared with WT mice (FIG. 1). These data suggested that host B7-H1 may regulate the extent of expansion and contraction of effector CD8<sup>+</sup> T cells, thus influencing the size of the memory CD8<sup>+</sup> T-cell pool in both lymphoid and non-lymphoid tissues.

**[0058]** Studies were conducted to examine the extent to which B7-H1 regulates the generation of memory CD8<sup>+</sup> T cells in immunized mice, using K<sup>b</sup>OVA<sub>257-264</sub> tetramer (K<sup>b</sup>OVA-tet) to detect antigen-primed memory CD8<sup>+</sup> T cells in the spleen on day 4 after *in vivo* restimulation (OVA protein, administered on day 40 after primary immunization). Day 4 was selected for analysis because at this time point it is possible to distinguish a recall response from the primary response (which takes 7 days to establish). Thus, naive mice did not show a significant increase of antigen-specific CD8<sup>+</sup> T cells on day 4 after immunization (FIG. 2A). The frequency of K<sup>b</sup>OVA-tet<sup>+</sup> CD8<sup>+</sup> T cells increased more than 2-fold in immunized B7-H1-deficient mice (0.38%) as compared with WT mice (0.16%; p < 0.05; FIG. 2A). This increase was reflected in the absolute cell numbers (p = 0.001; FIG. 2B). In addition to having increased numbers of memory CD8<sup>+</sup> T cells, an increased percentage of memory CD8<sup>+</sup> T cells capable of producing multiple cytokines was detected in the spleens of B7-H1-deficient mice (0.73% IFN $\gamma$ /TNF $\alpha$ +, 0.17% IFN $\gamma$ /IL-2+) as compared with WT mice (0.24% IFN $\gamma$ /TNF $\alpha$ +, 0.07% IFN $\gamma$ /IL-2+; p < 0.05; FIG. 2C). An *in vivo* CTL assay to measure cytolytic activity of the memory CD8<sup>+</sup> T cells also was performed. On day 4 after *in vivo* re-stimulation, OVA peptide- or control peptide-pulsed target cells (syngeneic splenocytes labeled with either high or low CFSE) were injected into immunized WT and B7-H1-deficient mice. Four hours following cell injection, the remaining CFSE positive cells in the spleen were analyzed. Memory CD8<sup>+</sup> T cells in the B7-H1-deficient mice lysed more OVA-peptide pulsed target cells (33.5%) than those in WT mice (9.3%, p < 0.01; FIG. 2D). Collectively, these data suggest that B7-H1 negatively regulates the generation of memory CD8<sup>+</sup> T cells in immunized mice.

**[0059]** A hallmark of memory CD8<sup>+</sup> T cells is their rapid recall response to cognate antigens, so studies were conducted to determine whether the increased memory pool in B7-H1-deficient mice would lead to a more protective recall response. B16-OVA melanoma tumor cells (engineered to express OVA) were injected into immunized WT and B7-H1-deficient mice. Intravenously injected B16-OVA tumor cells form metastases in the lung, and antitumor immunity can be monitored by counting the number of tumor foci. On day 4 following intravenous injection of  $5 \times 10^5$  B16-OVA tumor cells, the frequency of functional memory CD8<sup>+</sup> T cells in the lungs of WT and B7-H1-deficient mice was determined by intracellular staining for IFN $\gamma$ . About 4 to 5-fold more IFN $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells were detected in the lungs of B7-H1-deficient mice as compared with WT mice (p < 0.01; FIG. 3A). On day 21-post tumor injection, the number of tumor metastases in the lungs of naive B7-H1-deficient mice was comparable to that of naive WT mice (p = 0.43; FIG. 3B). Fewer tumor metastases formed in the lungs of immunized WT mice as compared with naive WT mice (p = 0.001). Significantly, tumor metastases were completely rejected in the lungs of immunized B7-H1-deficient mice (FIG. 3B), suggesting that a more efficient

CD8+ T-cell memory population is established in the absence of B7-H1.

Example 3 - Bim expression is reduced in antigen-primed CD8+ T cells in the absence of B7-H1

**[0060]** Studies were conducted to determine which mechanisms could be responsible for the increased population of memory CD8+ T cells in B7-H1-deficient mice by examining the proliferation and apoptosis of antigen-primed CD8+ T cells following immunization. CD11a was used as a surrogate activation marker. An advantage of this method is that CD11a<sup>high</sup> CD8+ T cells represent antigen-primed CD8+ T cells that are responsive to undefined antigen epitopes not recognized by tetramers. CD11a<sup>high</sup> CD8+ T cells were detected at low levels in the spleens of naive WT and B7-H1-deficient mice (FIG. 4A). On day 7 after immunization, the percentage of CD11a<sup>high</sup> CD8+ T cells increased more than 2-fold in the spleens of B7-H1-deficient mice (41.5%) as compared with immunized WT mice (17.2%;  $p < 0.01$ ; FIGS. 4A and 4B), consistent with the results obtained by tetramer staining (FIG. 1). Seven to 15% of CD11a<sup>high</sup> CD8+ T cells from WT and B7-H1-deficient mice were specific for the known H-2K<sup>b</sup>-restricted OVA<sub>257-264</sub> epitope based on tetramer staining, and CD11a<sup>low</sup> CD8+ T cells did not contain tetramer+ cells (FIG. 4C), suggesting that all antigen-specific CD8+ T cells are found in the CD11a<sup>high</sup> CD8+ T-cell population. In addition, the CD11a<sup>high</sup> CD8+ population from both WT and B7-H1-deficient mice, but not the CD11a<sup>low</sup> CD8+ T-cell population, produced IFN $\gamma$  and underwent degranulation (indicated by CD107a surface expression) following *ex vivo* re-stimulation (FIG. 4D). As T-cell responses against diverse epitopes are coordinately regulated, these data further support the concept that the CD11a<sup>high</sup> CD8+ T-cell population represents true OVA-specific CD8+ T cells. Nearly 80-90% of OVA-induced CD11a<sup>high</sup> CD8+ T cells were reactive against undefined antigen epitopes of the OVA protein (FIG. 4C). Therefore, the CD11a<sup>high</sup> CD8+ T-cell population could be used to represent a majority of the antigen-primed CD8+ T cells during primary T-cell responses. In the following studies, CD11a<sup>high</sup> was used as a marker to track antigen-specific CD8+ T cells.

**[0061]** The proliferation of effector CD8+ T cells following immunization was examined by staining cells for Ki67, a nuclear protein associated with cell proliferation (Gerdes et al. (1984) J. Immunol. 133:1710-1715). The percent of Ki67+ cells increased in CD11a<sup>high</sup> CD8+ T cells from B7-H1-deficient mice (9.32%) as compared with WT mice (7.5%), but this increase was not statistically significant (FIG. 5A). Proliferation also was monitored by performing a BrdU incorporation assay to measure the ongoing proliferation of CD8+ T cells following immunization. In this assay, the percentage of BrdU+ CD11a<sup>high</sup> CD8+ T cells also was similar between WT (6.05%) and B7-H1-deficient mice (5.59%; FIG. 5B). Ki67+ or BrdU+ cells were mainly detected in the CD11a<sup>high</sup> CD8+ T cells but not in CD11a<sup>low</sup> CD8+ T cells, suggesting that CD11a<sup>high</sup> CD8+ T cells are proliferating following antigen-stimulation (FIGS. 5A and 5B). These results suggested that the observed increased population of antigen-primed CD8+ T cells in B7-H1-deficient mice is not due to an increased proliferation of this cell compartment, as compared with WT mice.

**[0062]** Studies were then conducted to evaluate whether decreased apoptosis of antigen-primed CD8+ T cells could contribute to the observed increased population of antigen-primed CD8+ T cells in immunized B7-H1-deficient mice. As discussed above, the Fas/Fas ligand death receptor pathway is implicated in regulation of T-cell contraction, so the surface expression levels of Fas and Fas ligand on effector CD8+ T cells were measured on day 7 after immunization. Expression of Fas and Fas ligand was detected at similar levels in WT and B7-H1-deficient mice. These results suggest that the observed increased population of effector CD8+ T cells is not due to a change in Fas-induced apoptosis in B7-H1-deficient mice. The mitochondrial pathway for apoptosis was investigated by analyzing levels of Annexin V and tetramethylrhodamine ethyl ester (TMRE) staining. TMRE is a fluorescent marker that is incorporated into intact mitochondria, and cells undergoing apoptosis show reduced TMRE staining as compared with live cells (Jayaraman, J. Immunol. Methods 306:68-79, 2005). These studies revealed that fewer antigen-primed CD11a<sup>high</sup> CD8+ T cells were undergoing apoptosis (TMRE<sup>low</sup> Annexin V+) in B7-H1-deficient mice (3.4%) as compared with WT mice (6.7%,  $p < 0.05$ ; FIGS. 5C and 5D). These results suggested that decreased levels of mitochondrial apoptosis may contribute to the observed increased population of antigen-primed CD8+ T cells in B7-H1-deficient mice.

**[0063]** Experiments were conducted to look for alterations in the expression of apoptosis-regulating molecules in effector CD8+ T cells. Intracellular levels of the pro-apoptotic molecule Bim and the anti-apoptotic molecules Bcl-2 and Bcl-x<sub>L</sub> were measured in CD11a<sup>high</sup> CD8+ T cells freshly isolated from the spleen on day 7 after immunization of naive mice. Lower intracellular expression levels of Bim were observed in CD11a<sup>high</sup> CD8+ T cells from B7-H1-deficient mice than in the same cells obtained from WT mice ( $p < 0.001$ ; FIGS. 6A and 6B), while the expression levels of Bcl-2 and Bcl-x<sub>L</sub> were comparable in WT and B7-H1-deficient mice (FIG. 6A). The expression of Bim, Bcl-2 and Bcl-x<sub>L</sub> were comparable in CD11a<sup>low</sup> CD8+ T cells from B7-H1-deficient and WT mice (FIG. 6A). Intracellular expression levels of Bim also were analyzed in CD11a<sup>high</sup> CD8+ T cells isolated from the liver on day 7 after immunization of naive mice. Again, lower intracellular expression levels of Bim were observed in CD11a<sup>high</sup> CD8+ T cells from B7-H1-deficient mice as compared with WT mice (FIG. 6C). Finally, intracellular expression levels of these proteins were examined in CD11a<sup>high</sup> CD8+ T cells isolated from the spleen of naive mice, and no significant differences were observed in B7-H1-deficient vs. WT mice in the expression levels of Bim (FIG. 6D), Bcl-2 or Bcl-x<sub>L</sub>. These data suggested that the downregulation of the pro-apoptotic molecule Bim may contribute to the observed increased population of antigen-primed effector CD8+

T cells in B7-H1-deficient mice.

**[0064]** To exclude the possibility that the downregulation of Bim in B7-H1-deficient mice would be due to an intrinsic change in B7-H1-deficient T cells, transfer experiments were performed in which naive OT-1 CD8<sup>+</sup> T cells (Thy1.1<sup>+</sup>) were injected into WT or B7-H1-deficient mice (Thy1.2<sup>+</sup>). Following transfer of the OT-1 CD8<sup>+</sup> T cells, host mice were immunized with OVA plus poly I:C. On day 7 after immunization, the intracellular levels of Bim, Bcl-2, and Bcl-x<sub>L</sub> were measured in transferred OT-1 CD8<sup>+</sup> T cells freshly isolated from spleen and liver. OT-1 CD8<sup>+</sup> T cells transferred into B7-H1-deficient hosts expressed lower levels of Bim in both the spleen and liver as compared with the OT-1 CD8<sup>+</sup> T cells transferred into WT hosts (FIG. 7). The expression of Bcl-2 and Bcl-x<sub>L</sub> in OT-1 CD8<sup>+</sup> T cells transferred into WT or B7-H1-deficient mice was comparable (FIG. 7). These data suggested that the downregulation of Bim in B7-H1-deficient mice is not due to an intrinsic change in B7-H1-deficient T cells, but rather to host B7-H1 interacting with one of its binding partners on CD8<sup>+</sup> T cells.

**[0065]** Next, antibodies that block the interaction between B7-H1 and PD-1 or between B7-H1 and CD80 were used to examine if blocking either of these pathways would impact Bim expression levels. On days 1 and 3 after immunization of WT mice with OVA plus poly I:C, an anti-PD-1 antibody (G4) that only blocks PD-1 binding to B7-H1 (Hirano et al. (2005) Cancer Res. 65:1089-1096) or an anti-B7-H1 antibody (43H12) that only blocks B7-H1 binding to CD80 (Park et al. (2010) Blood 116:1291-1298) was injected. On day 7 after immunization, Bim expression levels in CD11a<sup>high</sup> CD8<sup>+</sup> T cells were compared between groups with or without antibody blockade. Antibodies blocking the interaction between B7-H1 and PD-1 or between B7-H1 and CD80 both reduced the expression of Bim in primed CD8<sup>+</sup> T cells as compared with control antibodies, whereas the expression of Bcl-2 and Bcl-x<sub>L</sub> remained unaffected. These results suggested that the downregulation of Bim in B7-H1-deficient mice might be due to a lack of interaction between B7-H1 and its binding partners, PD-1 and CD80.

**[0066]** After an acute viral infection, more central memory T cells accumulate in the lymphoid organs of PD-1-deficient mice as compared with WT mice, indicating that PD-1 signaling negatively regulates memory T-cell generation (Allie et al. (2011) J. Immunol. 186:6280-6286). The relevance of CD80 signaling in the regulation of memory generation was addressed by transferring equal numbers of CD80-deficient OT-1 and WT OT-1 naive CD8<sup>+</sup> T cells into CD45.1<sup>+</sup> mice. One day after T-cell transfer, host mice were immunized with OVA plus poly I:C. On day 21 after immunization, the frequency and phenotype of the transferred CD80-deficient and WT OT-1 CD8<sup>+</sup> T cells was analyzed. On day 21 after immunization, a 2-fold increased percentage of CD80-deficient OT-1 CD8<sup>+</sup> T cells as compared with WT OT-1 CD8<sup>+</sup> T cells was detected in the spleen, indicating that the transferred CD80-deficient OT-1 CD8<sup>+</sup> T cells generated more memory T cells as compared with WT OT-1 CD8<sup>+</sup> T cells. Surface staining confirmed that these cells had a central memory phenotype (CD44<sup>hi</sup> CD62L<sup>hi</sup>). The recall response of the memory population generated from transferred cells was investigated by injecting the hosts with OVA plus poly I:C on day 30 after the initial immunization, and 3 days later the frequency and phenotype of the transferred cells was analyzed. An increased percentage of CD80-deficient OT-1 CD8<sup>+</sup> T cells as compared with WT OT-1 CD8<sup>+</sup> T cells was detected in the spleen ( $p = 0.013$ ). Surface staining confirmed that these cells had an effector memory phenotype (CD44<sup>hi</sup> CD62L<sup>lo</sup>). Taken together, these data demonstrated that *Cd80*<sup>-/-</sup> OT-1 CD8<sup>+</sup> T cells generated more memory T cells as compared their WT counterparts, indicating that CD80 expressed by CD8<sup>+</sup> T cells may negatively regulate memory T-cell generation.

#### Example 4 - B7-H1 enhances Bim expression in activated CD8<sup>+</sup> T cells

**[0067]** Studies were conducted to investigate how B7-H1 might regulate Bim levels in activated CD8<sup>+</sup> T cells. Pre-activated WT CD8<sup>+</sup> T cells were incubated with platebound B7-H1 fusion protein for 48 hours in the presence of TCR stimulation (anti-CD3 antibody). Bim expression was analyzed by western blotting, and increased expression levels were observed in CD8<sup>+</sup> T cells cultured in the presence of B7-H1 fusion protein, as compared with a control fusion protein (FIG. 8A). Bim expression also was analyzed by intracellular flow cytometry, revealing that the B7-H1 fusion protein dramatically increased the levels of Bim protein in CD8<sup>+</sup> T cells compared with a control fusion protein ( $p < 0.02$ ; FIGS. 8B and 8C). In the absence of anti-CD3 antibodies, Bim levels did not increase upon incubation with B7-H1 fusion protein, suggesting that B7-H1 provides a co-stimulatory signal for Bim upregulation. Accordingly, the absolute number of live cells was also reduced in CD8<sup>+</sup> T cells cultured in the presence of B7-H1 fusion protein compared with a control protein ( $p < 0.01$ ; FIG. 8D). Increased levels of cells undergoing apoptosis (TMRE<sup>low</sup> Annexin V<sup>+</sup>) were observed in cultures of activated CD8<sup>+</sup> T cells exposed to the B7-H1 fusion protein and anti-CD3 (12.4%) as compared with cells cultured with control fusion protein and anti-CD3 (4.1%, FIG. 8E). The induction of apoptosis by B7-H1 fusion protein was lost in CD8<sup>+</sup> T cells isolated from Bim-deficient and Bcl-2 transgenic mice (FIG. 8E), suggesting that B7-H1-induced T-cell apoptosis may be dependent on the Bim-mediated mitochondrial pathway of apoptosis.

**[0068]** To examine which receptor of B7-H1 is involved in mediating Bim upregulation, pre-activated WT CD8<sup>+</sup> T cells were incubated with plate-bound B7-H1 fusion protein pre-blocked with anti-B7-H1 (10B5 or 43H12) or anti-PDI (G4) antibodies. The 10B5 antibody blocks the interaction of B7-H1 with both PD-1 and CD80. Both 10B5 and G4 antibodies completely blocked Bim upregulation induced by B7-H1 fusion protein, while 43H12 only partially, but significantly, did

so (FIG. 8F). None of the antibodies used in this experiment had effects on Bim expression levels in cells cultured with control fusion protein, indicating that their effect on Bim expression levels is due to blocking the interaction between B7-H1/PD-1 or B7-H1/CD80, and not due to a non-specific effect. These results suggest that B7-H1 may use PD-1 or CD80 on CD8+ T cells to deliver co-stimulatory signals for the upregulation of Bim.

**[0069]** The mechanism by which B7-H1 regulates Bim expression levels was then examined. mRNA levels of *Bcl211*, which encodes the Bim protein, were examined by quantitative real-time PCR analysis using mRNA isolated from pre-activated CD8+ T cells that were exposed to B7-H1 fusion protein or to a control fusion protein and anti-CD3 for 24 hours. Incubation of pre-activated CD8+ T cells with B7-H1 fusion protein did not increase the levels of *Bcl211* (FIG. 9A), indicating that the B7-H1-mediated upregulation of Bim does not result from transcriptional regulation. The degradation of Bim is tightly regulated, at least in part via the activation of Akt followed by Akt-mediated Bim phosphorylation and degradation (Qi et al. (2006) J. Biol. Chem. 281:813-823). The level of Akt activation in CD8+ T cells after B7-H1 engagement was measured by intracellular flow cytometry for phosphorylated-Akt (Ser473). CD8+ T cells cultured with B7-H1 fusion protein exhibited decreased levels of phosphorylated Akt as compared with CD8+ T cells cultured with a control fusion protein ( $p < 0.01$ ; FIGS. 9B and 9C). As phosphorylation of Akt at Ser473 is regulated by activation of mTOR (Sarbasov et al. (2005) Science 307:1098-1101; and Jacinto et al. (2006) Cell 127:125-137), studies were conducted to examine whether B7-H1 regulates phosphorylation of mTOR *in vitro*. Unexpectedly, there was no difference in levels of phospho-mTOR in CD8+ T cells cultured with B7-H1 fusion protein and cells cultured with control fusion protein (FIGS. 9B and 9C). These results suggested that CD8+ T-cell engagement with B7-H1 inhibits the activation of Akt, resulting in decreased degradation of Bim.

#### Example 5 - Bim is increased in tumor-reactive CD8+ T cells in peripheral blood of melanoma and prostate cancer patients

**[0070]** Peripheral blood lymphocytes were isolated from 26 patients with stage IV (advanced) melanoma, and from 11 healthy blood donors. Lymphocytes were stained with CD8, CD11a and PD-1 followed with intracellular staining for Bim. High expression of CD11a by CD8 T cells was used to identify antigen-primed T cells. Tumor-reactive CD8+ T cells were defined by their expression of CD11a<sup>high</sup> and PD-1+ (FIG. 13, left panel). The histograms shown in the right panel of FIG. 13 indicate expression of Bim by subsets of CD8+ T cells (Tn: T naive cells; PD-1-, PD-1 negative primed cells; PD-1+, PD-1 positive primed cells). Of note, only PD-1+ primed cells (tumor-reactive) CD8+ T cells expressed high levels of Bim. Bim expression was increased in tumor-reactive CD8+ T cells in peripheral blood of melanoma patients as compared to the healthy controls, and also was increased in tumor-reactive CD8+ T cells in peripheral blood of prostate cancer patients as compared to healthy controls (FIG. 14). The Bim upregulation in melanoma patients was PD-1 dependent, as depicted in FIG. 15. When levels of Bim were compared between PD-1 negative (PD-1-) and PD-1 positive (PD-1+) CD11a<sup>high</sup> CD8+ T cells, Bim was found to be significantly increased in the PD-1+ populations ( $p=0.0081$ ) in melanoma patients. In contrast, Bim expression was not increased in PD-1+ T cells in healthy donors, suggesting that Bim upregulation is dependent on PD-1 expression and is cancer-related.

**[0071]** Further, when melanoma patients were broken into "Bim low" vs. "Bim high" categories based on the level of Bim expression in tumor-reactive PD-1+ CD11a<sup>high</sup> CD8+ T cells in the peripheral blood (FIG. 16, left panel), the survival rate for patients with Bim<sup>high</sup> PD-1+ CD8+ T cells was reduced as compared to the survival rate for patients with Bim<sup>low</sup> PD-1+ CD8+ T cells (FIG. 16, right panel).

#### Example 6 - B7-H1 protein induces high expression of Bim in human pre-activated CD8+ T cells

**[0072]** Since Bim up-regulation is a consequence of interaction between B7-H1 and PD-1, experiments were conducted to test whether an anti-PD-1 blocking antibody can reduce B7-H1-induced Bim up-regulation in T cells. An *in vitro* system was established in which pre-activated human primary CD8+ T cells were incubated with a B7-H1/PD-L1 fusion protein to induce Bim up-regulation. As shown in FIG. 17A (right panel), a significant up-regulation of Bim (presented as MFI) was induced the B7-H1/PD-L1 fusion ( $P < 0.05$ ,  $n=6$ ). The increased Bim expression is further demonstrated by a flow cytometry histogram (FIG. 17A, left panel) and a Western blotting assay (FIG. 17B).

**[0073]** Using this system, several commercially available anti-human PD-1 antibodies were screened for their blocking effects, and one anti-PD-1 antibody (clone MIH4) was identified that significantly blocked B7-H1-induced Bim up-regulation in a dose dependent fashion (FIG. 18, left panel). Since B7-H1 induced different degrees of Bim up-regulation in individual healthy donors, experiments were conducted to examine whether different degrees of Bim up-regulation would affect the blocking effects of the anti-PD-1 antibody. Interestingly, it was observed that higher levels of Bim induced by B7-H1 had a negative correlation with Bim reduction by anti-PD-1 blocking antibody (FIG. 18, right panel; Pearson  $R = -0.71$ ,  $n = 12$ ,  $P < 0.05$ ). These results suggested that pre-existing Bim levels in CD8+ T cells might affect the efficiency of anti-PD-1 blockade. Thus, measuring Bim levels before treatment could help to determine the degree to which an anti-PD-1 antibody might block the impact of PD-1 signals on antitumor T cell responses.

Example 7 - Anti-PD-1 treatment reduced the frequency of Bim+ PD-1+ tumor-reactive CD8 T cells

**[0074]** Next, studies were conducted to evaluate the impact of the anti-PD-1 antibody on Bim expression by tumor-reactive CD8 T cells in cancer patients. Peripheral blood lymphocytes were collected from patients with advanced melanoma (Stage IV) before and 12 weeks post anti-PD-1 treatment. Tumor-reactive CD8 T cells were identified by their high expression of CD11a and expression of PD-1. Bim expression was analyzed by intracellular staining. The percentage of Bim+PD-1+ in CD11a<sup>high</sup> CD8+ T cells was compared between healthy people and melanoma patients, and between melanoma patients before and after treatment with anti-PD-1 antibody. As shown in FIG. 19, the frequency of Bim+PD-1+ CD8 T cells in the peripheral blood of melanoma patients (before treatment, n = 29) was significantly higher than in the healthy control group (p = 0.0012, n = 14), suggesting that more PD-1+ CD8 T cells are under the influence of the PD-1/B7-H1 interaction that leads to up-regulation of Bim. Importantly, twelve weeks after anti-PD-1 antibody therapy (2 mg/kg, one cycle), about 67% (6/9) of the melanoma patients demonstrated a significant reduction in the frequency of Bim+PD-1+ CD8 T cells (p = 0.023, n=6). These results indicated that measurement of Bim expressed by PD-1+ CD8 T cells could be used to monitor the responses of cancer patients to anti-PD-1 therapy, which may block B7-H1-induced Bim up-regulation. A reduced frequency or level of Bim expressed by PD-1+ CD8 T cells in cancer patients after anti-PD-1 therapy may be used to assess which patients are responsive to the therapy.

Example 8 - B7-H1 expressed by tumor cells induces Bim up-regulation in human pre-activated CD8 T cells

**[0075]** Since most human solid tumor cells express elevated levels of B7-H1, the function of tumor cell-expressed B7-H1 in T cell Bim expression was examined. Pre-activated human primary CD8 T cells were incubated with cells from a human melanoma line (624mel) that were transfected with B7-H1 cDNA or with control mock cDNA, for 24 hours. As shown in FIG. 20, intracellular expression of Bim was dramatically increased in CD8 T cells cultured with B7-H1/624mel cells, as compared to mock/624mel cells (p < 0.01). This result suggested that B7-H1 expressed by human tumor cells has the potential to up-regulate Bim in pre-activated CD8 T cells.

Example 9 - Bim expression is associated with B7-H1 expression in human RCC

**[0076]** The ability of B7-H1 to up-regulate Bim in pre-activated, but not newly activated, CD8+ T cells, implied that reactivation of tumor-reactive CD8+ T cells at tumor sites could be dampened through this mechanism by B7-H1 positive tumor cells. To test this possibility, human cancer tissues stained for B7-H1 and Bim were evaluated. The hypothesis was that B7-H1 positive human cancer tissues would be associated with more Bim positive tumor-infiltrating lymphocytes (TILs). As shown in FIG. 21 (left panel), human renal cell carcinoma tissues were stained with anti-B7-H1 and anti-Bim antibodies in immunohistochemistry assays. B7-H1 reactivity was identified on the surface of cancer cells, while Bim positive staining was identified on cancer cells and also on TILs (FIG. 21, left panel). Bim reactivity was determined by an arbitrary scoring system: 0 (absence), 1(focal), 2 (moderate), and 3 (marked). The association between B7-H1 positive or negative tumors and the frequency of Bim reactivity at different levels is demonstrated in the right panel of FIG. 21, and was analyzed using Fisher's exact test. B7-H1 positive tumors were found in general to have a higher degree (2-3 scores) of Bim positive TILs than B7-H1 negative tumors (Fisher's exact test, p<0.01). These results suggest that B7-H1 positive tumors can induce more death in tumor-reactive T cells at tumor sites via up-regulation of Bim when these T cells are re-activated with tumor antigen stimulation.

Example 10 - Bim expression is correlated with Granzyme B and T-bet expressed by cancer-related PD-1+ CD11a<sup>high</sup> CD8+ T cells

**[0077]** To examine whether up-regulation of Bim is associated with effector T cells, the levels of Granzyme B (an executive molecule of cytotoxic T lymphocytes, CTL) and T-bet (a transcription factor of CTL) were measured in PD-1+ CD11a<sup>high</sup> CD8 T cells from the blood of melanoma patients, and their correlation to Bim levels was analyzed. As shown in FIG. 22, positive correlations between levels of Bim and Granzyme B (left panel; r = 0.51, p < 0.05) and between levels of Bim and T-bet (right panel; r = 0.62, p < 0.01) were observed. These results suggested that higher levels of Bim expression are associated with effector T cell differentiation or function. These data also imply that up-regulation of Bim may be used by B7-H1 positive tumor cells to induce apoptosis of tumor-reactive CD8 T cells, especially of CD8 T cells with effector function.

Example 11 - Bim expression declines in PD-1+ CD11a<sup>high</sup> CD8 T cells following radiotherapy in some cancer patients

**[0078]** To observe how the levels of Bim in tumor-reactive CD8 T cells respond to therapy, Bim levels were measured in PD-1+ CD11a<sup>high</sup> CD8 T cells from the peripheral blood of patients with melanoma and prostate cancers before and

post radiotherapy. As shown in FIG. 23 (left panel), decreased levels of Bim were observed in melanoma patients post radiotherapy. In contrast, increased levels of Bim were observed in prostate cancer patients post radiotherapy (right panel). Due to the limited numbers of patients in this study, these changes did not reach statistical significance. However, these changes in Bim levels after tumor cytotoxic therapy suggested that destruction of tumor tissues could alter the antigen stimulation and B7-H1 expression that would result in alterations in Bim expression, which is dependent on both antigen stimulation and B7-H1 engagement with PD-1 on CD8 T cells. Taken together, these studies indicate that measurement of Bim levels in tumor-reactive PD-1 + CD8 T cells could be used as a biomarker to monitor T cell responses to antigens and PD-1 ligands (e.g., B7-H1) expressed by human tumor cells.

## OTHER EMBODIMENTS

**[0079]** It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

## SEQUENCE LISTING

### [0080]

<110> Mayo Foundation for Medical Education and Research

<120> METHODS FOR TREATING CANCER IN PATIENTS  
WITH ELEVATED LEVELS OF BIM

<130> 07039-1283WO1

<150> US 61/885,218

<151> 2013-10-01

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 873

<212> DNA

<213> Homo sapiens

<400> 1

```

atgaggatat ttgctgtctt tatattcatg acctactggc atttgctgaa cgcattttact 60
gtcacgggttc ccaaggacct atatgtggta gagtatggta gcaatatgac aattgaatgc 120
aaattcccag tagaaaaaca attagacctg gctgcactaa ttgtctattg ggaaatggag 180
gataagaaca ttattcaatt tgtgcatgga gaggaagacc tgaagggttca gcatagtagc 240
tacagacaga gggcccggct gttgaaggac cagctctccc tgggaaatgc tgcacttcag 300
atcacagatg tgaaattgca ggatgcaggg gtgtaccgct gcatgatcag ctatggtggt 360
gccgactaca agcgaattac tgtgaaagtc aatgccccat acaacaaaat caaccaaaga 420
attttggttg tggatccagt cacctctgaa catgaactga catgtcaggc tgaggggtac 480
cccaaggccg aagtcatctg gacaagcagt gaccatcaag tcctgagtgg taagaccacc 540
accaccaatt ccaagagaga ggagaagctt ttcaatgtga ccagcacact gagaatcaac 600
acaacaacta atgagatttt ctactgcact tttaggagat tagatcctga ggaaaaccat 660
acagctgaat tggatcatcc agaactacct ctggcacatc ctccaaatga aaggactcac 720
ttggttaattc tgggagccat cttattatgc cttggtgtag cactgacatt catcttccgt 780
ttaagaaaag ggagaatgat ggatgtgaaa aaatgtggca tccaagatac aaactcaaag 840
aagcaaagtg atacacattt ggaggagacg taa                                     873

```

<210> 2

<211> 290

EP 3 052 131 B1

<212> PRT

<213> Homo sapiens

<400> 2

5

10

15

20

25

30

35

40

45

50

55

```

Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu
 1      5      10      15
Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr
      20      25      30
Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu
      35      40      45
Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile
 50      55      60
Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser
65      70      75      80
Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn
      85      90      95
Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr
      100      105      110
Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val
      115      120      125
Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val

      130      135      140
Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr
145      150      155      160
Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser
      165      170      175
Gly Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn
      180      185      190
Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr
      195      200      205
Cys Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu
 210      215      220
Val Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His
225      230      235      240
Leu Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr
      245      250      255
Phe Ile Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys
      260      265      270
Gly Ile Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu
      275      280      285
Glu Thr
 290

```

<210> 3

<211> 948

<212> DNA

<213> Homo sapiens

<400> 3

# EP 3 052 131 B1

5  
10  
15

```

gcctgagcag tggagaaggc ggcactctgg tggggctgct ccaggcatgc agatcccaca 60
ggcgccctgg ccagtcgtct gggcggtgct acaactgggc tggcggccag gatggttctt 120
agactcccca gacaggccct ggaaccccc cacttctcc ccagccctgc tcgtggtgac 180
cgaaggggac aacgccacct tcacctgcag cttctccaac acatcggaga gcttcgtgct 240
aaactggtac cgcattgagcc ccagcaacca gacggacaag ctggccgctt tccccgagga 300
ccgcagccag cccggccagg actgccgctt ccgtgtcaca caactgcccc acgggctga 360
cttcacatg agcgtggtca gggcccggcg caatgacagc ggcacctacc tctgtggggc 420
catctccctg gcccccaagg cgcagatcaa agagagcctg cgggcagagc tcagggtgac 480
agagagaagg gcagaagtgc ccacagcccc cccagcccc tcacccaggc cagccggcca 540
gttccaaacc ctggtggttg gtgtcgtggg cggcctgctg ggcagcctgg tgctgctagt 600
ctgggtcctg gccgtcatct gctcccgggc cgcacgaggg acaataggag ccaggcgcac 660
cggccagccc ctgaaggagg acccctcagc cgtgcctgtg ttctctgtgg actatgggga 720
gctggatttc cagtggcgag agaagacccc ggagccccc gtgccctgtg tccctgagca 780
gacggagtat gccaccattg tctttcctag cggaatgggc acctcatccc ccgcccgcag 840
gggctcagcc gacggccctc ggagtgccca gccactgagg cctgaggatg gacactgctc 900
ttggcccctc tgaccggctt ccttggccac cagtgttctg cagaccct 948

```

<210> 4

<211> 288

20 <212> PRT

<213> Homo sapiens

<400> 4

25  
30  
35  
40  
45  
50  
55

```

Met Gln Ile Pro Gln Ala Pro Trp Pro Val Val Trp Ala Val Leu Gln
 1           5           10           15
Leu Gly Trp Arg Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp
          20           25           30
Asn Pro Pro Thr Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp
          35           40           45
Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val
          50           55           60
Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala
65           70           75           80
Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg

```

# EP 3 052 131 B1

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    |     |     |     | 85  |     |     |     | 90  |     |     |     |     | 95  |     |     |     |
|    | Val | Thr | Gln | Leu | Pro | Asn | Gly | Arg | Asp | Phe | His | Met | Ser | Val | Val | Arg |
|    |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| 5  | Ala | Arg | Arg | Asn | Asp | Ser | Gly | Thr | Tyr | Leu | Cys | Gly | Ala | Ile | Ser | Leu |
|    |     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
|    | Ala | Pro | Lys | Ala | Gln | Ile | Lys | Glu | Ser | Leu | Arg | Ala | Glu | Leu | Arg | Val |
|    |     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
|    | Thr | Glu | Arg | Arg | Ala | Glu | Val | Pro | Thr | Ala | His | Pro | Ser | Pro | Ser | Pro |
|    | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| 10 | Arg | Pro | Ala | Gly | Gln | Phe | Gln | Thr | Leu | Val | Val | Gly | Val | Val | Gly | Gly |
|    |     |     |     | 165 |     |     |     |     |     | 170 |     |     |     |     | 175 |     |
|    | Leu | Leu | Gly | Ser | Leu | Val | Leu | Leu | Val | Trp | Val | Leu | Ala | Val | Ile | Cys |
|    |     |     | 180 |     |     |     |     |     | 185 |     |     |     | 190 |     |     |     |
|    | Ser | Arg | Ala | Ala | Arg | Gly | Thr | Ile | Gly | Ala | Arg | Arg | Thr | Gly | Gln | Pro |
| 15 |     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
|    | Leu | Lys | Glu | Asp | Pro | Ser | Ala | Val | Pro | Val | Phe | Ser | Val | Asp | Tyr | Gly |
|    |     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
|    | Glu | Leu | Asp | Phe | Gln | Trp | Arg | Glu | Lys | Thr | Pro | Glu | Pro | Pro | Val | Pro |
|    | 225 |     |     |     |     | 230 |     |     |     | 235 |     |     |     |     |     | 240 |
| 20 | Cys | Val | Pro | Glu | Gln | Thr | Glu | Tyr | Ala | Thr | Ile | Val | Phe | Pro | Ser | Gly |
|    |     |     |     | 245 |     |     |     |     |     | 250 |     |     |     |     | 255 |     |
|    | Met | Gly | Thr | Ser | Ser | Pro | Ala | Arg | Arg | Gly | Ser | Ala | Asp | Gly | Pro | Arg |
|    |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |     |
|    | Ser | Ala | Gln | Pro | Leu | Arg | Pro | Glu | Asp | Gly | His | Cys | Ser | Trp | Pro | Leu |
|    |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |

<210> 5  
 <211> 2757  
 <212> DNA  
 <213> Homo sapiens

<400> 5

EP 3 052 131 B1

|    |             |             |             |             |             |             |      |
|----|-------------|-------------|-------------|-------------|-------------|-------------|------|
|    | gacaagtact  | gagtgaactc  | aaaccctctg  | taaagtaaca  | gaagttagaa  | ggggaaatgt  | 60   |
|    | cgcctctctg  | aagattaccc  | aaagaaaaag  | tgatttgtca  | ttgctttata  | gactgtaaga  | 120  |
|    | agagaacatc  | tcagaagtgg  | agtcttacct  | tgaaatcaaa  | ggattttaaag | aaaaagtggg  | 180  |
| 5  | atTTTTcttc  | agcaagctgt  | gaaactaaat  | ccacaacctt  | tggagaccca  | ggaacacctt  | 240  |
|    | ccaatctctg  | tgtgttttgt  | aaacatcact  | ggagggtctt  | ctacgtgagc  | aattggattg  | 300  |
|    | tcatcagccc  | tgcctgtttt  | gcacctggga  | agtgccctgg  | tcttacttgg  | gtccaaattg  | 360  |
|    | ttggcttttca | cttttgaccc  | taagcatctg  | aagccatggg  | ccacacacgg  | aggcagggaa  | 420  |
|    | catcaccatc  | caagtgtcca  | tacctcaatt  | tctttcagct  | cttggtgctg  | gctggtcttt  | 480  |
|    | ctcacttctg  | ttcaggtgtt  | atccacgtga  | ccaaggaagt  | gaaagaagtg  | gcaacgctgt  | 540  |
| 10 | cctgtggtca  | caatgtttct  | gttgaagagc  | tggcacaaac  | tgcgcatctac | tggcaaaagg  | 600  |
|    | agaagaaaat  | ggtgctgact  | atgatgtctg  | gggacatgaa  | tatatggccc  | gagtacaaga  | 660  |
|    | accggaccat  | ctttgatata  | actaataacc  | tctccattgt  | gatcctggct  | ctgcgcccac  | 720  |
|    | ctgacgaggg  | cacatacgag  | tgtgttgttc  | tgaagtatga  | aaaagacgct  | ttcaagcggg  | 780  |
|    | aacacctggc  | tgaagtgcag  | ttatcagtc   | aagctgactt  | ccctacacct  | agtatatctg  | 840  |
| 15 | actttgaaat  | tccaacttct  | aatattagaa  | ggataatttg  | ctcaacctct  | ggagggttttc | 900  |
|    | cagagcctca  | cctctcctgg  | ttggaaaaatg | gagaagaatt  | aaatgccatc  | aacacaacag  | 960  |
|    | tttcccaaga  | tcctgaaact  | gagctctatg  | ctgttagcag  | caaactggat  | ttcaatatga  | 1020 |
|    | caaccaacca  | cagcttcatg  | tgtctcatca  | agtatggaca  | tttaagagtg  | aatcagacct  | 1080 |
|    | tcaactggaa  | tacaaccaag  | caagagcatt  | ttcctgataa  | cctgctccca  | tcctggggcca | 1140 |
| 20 | ttaccttaat  | ctcagtaaat  | ggaatttttg  | tgatatgctg  | cctgacctac  | tgctttgccc  | 1200 |
|    | caagatgcag  | agagagaagg  | aggaatgaga  | gattgagaag  | ggaaagtgtg  | cgccctgtat  | 1260 |
|    | aacagtgtcc  | gcagaagcaa  | ggggctgaaa  | agatctgaag  | gtcccacctc  | catttgcaat  | 1320 |
|    | tgacctcttc  | tgggaacttc  | ctcagatgga  | caagattacc  | ccaccttgcc  | ctttacgtat  | 1380 |
|    | ctgctcttag  | gtgcttcttc  | acttcagttg  | ctttgcagga  | agtgtctaga  | ggaatatggg  | 1440 |
| 25 | gggcacagaa  | gtagctctgg  | tgaccttgat  | caagggtgtt  | tgaaatgcag  | aattcttgag  | 1500 |
|    | ttctggaagg  | gacttttagag | aataccagtg  | ttattaatga  | caaaggcact  | gaggcccagg  | 1560 |
|    | gaggtgaccc  | gaattataaa  | ggccagcgcc  | agaaccacga  | tttcctaact  | ctgggtgctct | 1620 |
|    | ttccctttat  | cagtttgact  | gtggcctgtt  | aactgggtata | tacatatata  | tgctcaggcaa | 1680 |
|    | agtgtgtctg  | gaagtagaat  | ttgtccaata  | acagggtcaac | ttcagagact  | atctgatttc  | 1740 |
| 30 | ctaattgtcag | agtagaagat  | tttatgctgc  | tgtttataaaa | agcccaatgt  | aatgcatagg  | 1800 |
|    |             |             |             |             |             |             |      |
|    | aagtatggca  | tgaacatctt  | taggagacta  | atggaaatat  | tattggtgtt  | taccagctat  | 1860 |
|    | tccatttttt  | tcattgtgtt  | ctctattgct  | gctctctcac  | tcccccatga  | ggtacagcag  | 1920 |
|    | aaaggagAAC  | tatccaaaac  | taatttcctc  | tgacatgtaa  | gacgaatgat  | ttaggtacgt  | 1980 |
| 35 | caaagcagta  | gtcaaggagg  | aaagggatag  | tccaaagact  | taactgggtc  | atattggact  | 2040 |
|    | gataatctct  | ttaaatggct  | ttatgctagt  | ttgacctcat  | ttgtaaaata  | tttatgagaa  | 2100 |
|    | agttctcatt  | taaaatgaga  | tcgttggtta  | cagtgtatgt  | actaagcagt  | aagctatctt  | 2160 |
|    | caaagtgtcta | aggtagtaac  | tttccatagg  | gcctccttag  | atccctaaga  | tggttttttc  | 2220 |
|    | tccttggtat  | ttctgggtct  | ttctgacatc  | agcagagaac  | tggaagaca   | tagccaactg  | 2280 |
| 40 | ctgttcatgt  | tactcatgac  | tcctttctct  | aaaactgcct  | tccacaattc  | actagaccag  | 2340 |
|    | aagtggacgc  | aacttaagct  | gggataatca  | cattatcatc  | tgaaaatctg  | gagttgaaca  | 2400 |
|    | gcaaaagaag  | acaacatttc  | tcaaatgcac  | atctcatggc  | agctaagcca  | catggctggg  | 2460 |
|    | atttaaagcc  | tttagagcca  | gcccattggc  | ttagctacct  | cactatgctg  | cttcacaaac  | 2520 |
|    | cttgctcctg  | tgtaaaacta  | tattctcagt  | gtagggcaga  | gaggtctaac  | accaacataa  | 2580 |
|    | ggtactagca  | gtgtttcccg  | tattgacagg  | aatacttaac  | tcaataattc  | ttttcttttc  | 2640 |
| 45 | catttagtaa  | cagttgtgat  | gactatgttt  | ctattctaag  | taattcctgt  | attctacagc  | 2700 |
|    | agatactttg  | tcagcaatac  | taagggaaga  | aacaaagtgt  | aaccgtttct  | ttaataa     | 2757 |

<210> 6

<211> 288

50 <212> PRT

<213> Homo sapiens

<400> 6

55

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Met | Gly | His | Thr | Arg | Arg | Gln | Gly | Thr | Ser | Pro | Ser | Lys | Cys | Pro | Tyr |
|    | 1   |     |     |     | 5   |     |     |     | 10  |     |     |     |     | 15  |     |     |
|    | Leu | Asn | Phe | Phe | Gln | Leu | Leu | Val | Leu | Ala | Gly | Leu | Ser | His | Phe | Cys |
|    |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| 5  | Ser | Gly | Val | Ile | His | Val | Thr | Lys | Glu | Val | Lys | Glu | Val | Ala | Thr | Leu |
|    |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
|    | Ser | Cys | Gly | His | Asn | Val | Ser | Val | Glu | Glu | Leu | Ala | Gln | Thr | Arg | Ile |
|    |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
|    | Tyr | Trp | Gln | Lys | Glu | Lys | Lys | Met | Val | Leu | Thr | Met | Met | Ser | Gly | Asp |
| 10 | 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
|    | Met | Asn | Ile | Trp | Pro | Glu | Tyr | Lys | Asn | Arg | Thr | Ile | Phe | Asp | Ile | Thr |
|    |     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
|    | Asn | Asn | Leu | Ser | Ile | Val | Ile | Leu | Ala | Leu | Arg | Pro | Ser | Asp | Glu | Gly |
|    |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| 15 | Thr | Tyr | Glu | Cys | Val | Val | Leu | Lys | Tyr | Glu | Lys | Asp | Ala | Phe | Lys | Arg |
|    |     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
|    | Glu | His | Leu | Ala | Glu | Val | Thr | Leu | Ser | Val | Lys | Ala | Asp | Phe | Pro | Thr |
|    |     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
|    | Pro | Ser | Ile | Ser | Asp | Phe | Glu | Ile | Pro | Thr | Ser | Asn | Ile | Arg | Arg | Ile |
|    | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| 20 | Ile | Cys | Ser | Thr | Ser | Gly | Gly | Phe | Pro | Glu | Pro | His | Leu | Ser | Trp | Leu |
|    |     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
|    | Glu | Asn | Gly | Glu | Glu | Leu | Asn | Ala | Ile | Asn | Thr | Thr | Val | Ser | Gln | Asp |
|    |     |     |     | 180 |     |     |     | 185 |     |     |     |     | 190 |     |     |     |
|    | Pro | Glu | Thr | Glu | Leu | Tyr | Ala | Val | Ser | Ser | Lys | Leu | Asp | Phe | Asn | Met |
| 25 |     |     |     | 195 |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
|    | Thr | Thr | Asn | His | Ser | Phe | Met | Cys | Leu | Ile | Lys | Tyr | Gly | His | Leu | Arg |
|    |     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
|    | Val | Asn | Gln | Thr | Phe | Asn | Trp | Asn | Thr | Thr | Lys | Gln | Glu | His | Phe | Pro |
|    | 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |
| 30 | Asp | Asn | Leu | Leu | Pro | Ser | Trp | Ala | Ile | Thr | Leu | Ile | Ser | Val | Asn | Gly |
|    |     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |
|    | Ile | Phe | Val | Ile | Cys | Cys | Leu | Thr | Tyr | Cys | Phe | Ala | Pro | Arg | Cys | Arg |
|    |     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
|    | Glu | Arg | Arg | Arg | Asn | Glu | Arg | Leu | Arg | Arg | Glu | Ser | Val | Arg | Pro | Val |
| 35 |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |

## Claims

### 1. Composition comprising

an anti-B7-H1 antibody, an anti-PD-1 antibody, an anti-CD80 antibody, a fusion protein comprising a portion of PD-1 linked to an immunoglobulin Fc sequence, or a fusion protein comprising a portion of CD80 linked to an immunoglobulin Fc sequence

for use in a method for treating a mammal having cancer,

wherein said method comprises

(i) determining the level of Bim in a peripheral blood sample from said mammal, and identifying said mammal as containing an elevated level of Bim, wherein said elevated level of Bim is based on Bim protein levels, wherein said elevated level of Bim refers to a level that is at least 50% greater than a reference level of Bim, wherein said reference level of Bim refers to the level of Bim typically observed in healthy corresponding mammals without cancer, and

(ii) administering said composition to said mammal under conditions wherein the interaction of naturally-occurring B7-H1 with PD-1 or CD80 in said mammal is reduced after administering said composition to said mammal.

### 2. The composition for the use according to claim 1, wherein said mammal is a human.

### 3. The composition for the use according to claim 1, wherein said cancer is a melanoma cancer, a breast cancer, a lung cancer, a renal cell carcinoma cancer, a pancreas cancer, a prostate cancer, a colon cancer, a brain cancer, a liver cancer, or an ovarian cancer.

**Patentansprüche**

1. Zusammensetzung, umfassend  
 einen Anti-B7-H1-Antikörper, einen Anti-PD-1-Antikörper, einen Anti-CD80-Antikörper, ein einen Teil von PD-1 verknüpft mit einer Immunglobulin-Fc-Sequenz umfassendes Fusionsprotein oder ein einen Teil von CD80 verknüpft mit einer Immunglobulin-Fc-Sequenz umfassendes Fusionsprotein,  
 zur Verwendung bei einem Verfahren zur Behandlung eines an Krebs leidenden Säugers,  
 wobei das Verfahren Folgendes umfasst:
  - (i) Bestimmen des Spiegels von Bim in einer Probe von peripherem Blut aus dem Säuger und Nachweisen, dass der Säuger einen erhöhten Bim-Spiegel enthält, wobei der erhöhte Bim-Spiegel auf Bim-Protein-Spiegeln beruht,  
 wobei sich der erhöhte Bim-Spiegel auf einen Spiegel bezieht, der wenigstens 50% höher ist als ein Bim-Referenzspiegel, wobei sich der Bim-Referenzspiegel auf den Bim-Spiegel bezieht, der typischerweise bei entsprechenden gesunden Säugern ohne Krebs beobachtet wird, und
  - (ii) Verabreichen der Zusammensetzung an den Säuger unter Bedingungen, wobei die Wechselwirkung von natürlich vorkommendem B7-H1 mit PD-1 oder CD80 in dem Säuger nach Verabreichen der Zusammensetzung an den Säuger verringert ist.
2. Zusammensetzung zur Verwendung nach Anspruch 1, wobei es sich bei dem Säuger um einen Menschen handelt.
3. Zusammensetzung zur Verwendung nach Anspruch 1, wobei es sich bei dem Krebs um eine Melanom-Krebserkrankung, eine Brustkrebserkrankung, eine Lungenkrebserkrankung, eine Nierenzellkarzinom-Krebserkrankung, eine Bauchspeicheldrüsenkrebserkrankung, eine Prostatakrebserkrankung, eine Darmkrebserkrankung, einen Hirntumor, eine Leberkrebserkrankung oder ein Ovarialkarzinom handelt.

**Revendications**

1. Composition comprenant  
 un anticorps anti-B7-H1, un anticorps anti-PD-1, un anticorps anti-CD80, une protéine de fusion comprenant une partie de PD-1 liée à une séquence Fc d'immunoglobuline, ou une protéine de fusion comprenant une partie de CD80 liée à une séquence Fc d'immunoglobuline pour utilisation dans un procédé de traitement d'un mammifère ayant un cancer, ledit procédé comprenant
  - (i) la détermination du taux de Bim dans un échantillon de sang périphérique dudit mammifère et l'identification dudit mammifère comme contenant un taux élevé de Bim, ledit taux élevé de Bim étant basé sur les taux de protéine Bim,  
 ledit taux élevé de Bim désignant un taux qui est au moins 50 % plus élevé qu'un taux de référence de Bim, ledit taux de référence de Bim désignant le taux de Bim typiquement observé chez des mammifères correspondants sains sans cancer, et
  - (ii) l'administration de ladite composition audit mammifère dans des conditions dans lesquelles l'interaction de B7-H1 d'origine naturelle avec PD-1 ou CD80 dans ledit mammifère est réduite après l'administration de ladite composition audit mammifère.
2. Composition pour l'utilisation selon la revendication 1, ledit mammifère étant un humain.
3. Composition pour l'utilisation selon la revendication 1, ledit cancer étant un cancer de type mélanome, un cancer du sein, un cancer du poumon, un carcinome à cellules rénales, un cancer du pancréas, un cancer de la prostate, un cancer du côlon, un cancer du cerveau, un cancer du foie ou un cancer de l'ovaire.

FIGURE 1




FIGURE 2




FIGURE 3





FIGURE 4







FIG. 5

FIGURE 6



**FIGURE 7**




FIGURE 8





FIGURE 9



## FIGURE 10

```

1 atgaggatat ttgctgtctt tatattcatg acctactggc atttgctgaa cgcatttact
61 gtcacgggtc ccaaggacct atatgtggtgta gagtatggta gcaatatgac aattgaatgc
121 aaattcccag tagaaaaaca attagacctg gctgcactaa ttgtctattg ggaatggag
181 gataagaaca ttattcaatt tgtgcatgga gaggaagacc tgaagggttca gcatagtagc
241 tacagacaga gggcccggtt gttgaaggac cagctctccc tgggaaatgc tgcacttcag
301 atcacagatg tgaattgca ggtgcagggt gtgtaccgtt gcatgatcag ctatggtggt
361 gccgactaca agcgaattac tgtgaaagtc aatgccccat acaacaaat caacaaaga
421 attttggtg tggatccagt cacctctgaa catgaaactga catgtcaggc tgagggtac
481 cccaaggccg aagtcacctg gacaagcagt gaccatcaag tcctgagtgg taagaccacc
541 accaccaatt ccaagagaga ggagaagctt ttcaatgtga ccagcacact gagaatcaac
601 acaacaacta atgagatttt ctactgcact tttaggagat tagatcctga ggaaccat
661 acagctgaat tggatcatccc agaactacct ctggcacatc ctccaaatga aaggactcac
721 ttggtaatc tgggagccat cttattatgc cttggtgtag cactgacatt catcttccgt
781 ttaagaaaag ggagaatgat ggatgtgaaa aaatgtggca tccaagatc aaactcaaag
841 aagcaaatg atacacattt ggaggagacg taa (SEQ ID NO:1)

1 MRIFAVFIFM TYWHLNNAFT VTVPKDLVV EYGSNMTIEC KFPVEKQLDL AALIVYWEME
61 DKNIIQFVHG EEDLKVQHSS YRQARLLKD QLSLGNAAALQ ITDVKLQDAG VYRCMISYGG
121 ADYKRITVKV NAPYNKINQR ILVVDPTSE HELTCAEGY PKAEVIWTSS DHQVLSGKTT
181 TTNSKREEKL FNVSTLRIN TTTNEIFYCT FRRLDPEENH TAEELVPELP LAHPPNERH
241 LVILGAILLC LGVALTFIFR LRKGRMDVK KCGIQDTNSK KQSDTHLEET (SEQ ID NO:2)

```

FIGURE 11

```

1  gcctgagcag  tggagaaggc  ggcactctgg  tggggctgct  ccaggcatgc  agatcccaca
61  ggcgccctgg  ccagtcgtct  gggcggtgct  acaactgggc  tggcgggccag  gatggttctt
121  agactcccca  gacaggccct  ggaaccccc  caccttctcc  ccagccctgc  tcgtggtgac
181  cgaaggggac  aacgccacct  tcacctgcag  ctctccaac  acatcggaga  gcttcgtgct
241  aaactggtac  cgcatagacc  ccagcaacca  gacggacaag  ctggccgctt  tccccgagga
301  ccgcagccag  ccgggccagg  actgccgctt  ccgtgtcaca  caactgccc  acgggcgtga
361  ctccacatg  agcgtggtca  gggcccgcg  caatgacagc  ggcacctacc  tctgtggggc
421  catctccctg  gcccccaagg  cgcatatcaa  agagagcctg  cgggcagagc  tcagggtgac
481  agagagaagg  gcagaaagtgc  ccacagccc  cccagcccc  tcaccaggc  cagccggcca
541  gttccaaacc  ctggtggttg  gtgtcgtggg  cgccctgctg  ggcagcctgg  tctgtctagt
601  ctgggtcctg  gccgtcatct  gctcccggc  cgcacgagg  acaataggag  ccaggcgcac
661  cggccagccc  ctgaaggagg  accctcagc  cgtgcctgtg  ttctctgtgg  actatgggga
721  gctggatttc  cagtggcgag  agaagacccc  ggagccccc  gtgccctgtg  tccctgagca
781  gacggagtat  gccaccattg  tctttcctag  cggaaatggg  acctatccc  ccgcccgcag
841  gggctcagcc  gacggccctc  ggagtgcaca  gccactgagg  cctgaggatg  gacactgctc
901  ttggccccctc  tgaccgggctt  ccttggccac  cagtgttctg  cagaccct  (SEQ ID NO:3)

1  MQIPQAPWPV  VWAVLQLGWR  PGWFLDSPDR  PWNPTTFSPA  LLVVTEGDNA  TFTCSFSNTS
61  ESFVLNWYRM  SPSNQTDKLA  AFPEDRSQPG  QDCRFRVTQL  PNGRDFHMSV  VRARNDSGT
121  YLCGAISLAP  KAQIKESLRA  ELRVTERRAE  VPTAHPSPSP  RPAGQFQTLV  VGVVGLLGS
181  LVLLVWVLAV  ICSRAARGTI  GARRTGQPLK  EDPSAVPVFS  VDYGELDFQW  REKTPEPPVP
241  CVPEQTEYAT  IVFPSGMGTS  SPARRGSADG  PRSAQPLRPE  DGHCSWPL  (SEQ ID NO:4)

```

**FIGURE 12A**

```

1  gacaaagtact  gagtgaactc  aaaccctctg  taaagtaaca  gaagttagaa  ggggaaatgt  cgcctctctg  aagattaccc
81  aaagaaaaag  tgatttgtca  ttgctttata  gactgtaaga  agagaacatc  tcagaagtgg  agtcttacc  tgaatatcaaa
161  ggatttaaa  aaaaagtga  atttttcttc  agcaagctgt  gaaactaaat  ccacaacctt  tggagaccca  ggaacacctt
241  ccaatctctg  tgtgttttgt  aaacatcact  ggagggtctt  ctacgtgagc  aattggattg  tcatcagccc  tgcctgtttt
321  gcacctggga  agtgccttgg  tcttacttgg  gtccaaattg  ttggctttca  cttttgaccc  taagcatctg  aagccatggg
401  ccacacacgg  aggcagggaa  catcaccatc  caagtgtcca  tacctcaatt  tctttcagct  ctgtgtctgt  gctggctctt
481  ctcacttctg  ttcaggtgtt  atccacgtga  ccaaggaaat  gaaagaagt  gcaacgctgt  cctgttgtca  caatgtttct
561  gttgaagagc  tggcacaaa  tgcacatctc  tggcaaaaag  agaagaaaat  ggtgtgtact  atgatgtctg  gggacatgaa
641  tatatggccc  gagtacaaga  accggacctc  ctttgatatc  actaataaac  tctccattgt  gatcctggct  ctgcgcccac
721  ctgacgaggg  cacatacgag  tgtgttgttc  tgaagtatga  aaaagacgct  ttcaagcggg  aacacctggc  tgaagtgcg
801  ttatcagtca  aagctgactt  cctacacct  agtatatctg  actttgaaat  tccaacttct  aatattagaa  ggataatttg
881  ctcaacctct  ggaggttttc  cagagcctca  cctctcctgg  ttggaaaatg  gagaagaatt  aatgccatc  aacacaacag
961  tttcccaaga  tcctgaaact  gagctctatg  ctgttagcag  caaactggat  ttcaatatga  caaccaacca  cagcttcatg
1041  tgtctcatca  agtatggaca  tttaagagt  aatcagacct  tcaactggaa  tacaaccaag  caagacatt  ttcctgataa
1121  cctgctccca  tcctgggcca  ttaccttaat  ctcagtaaat  ggaatttttg  tgatatgtctg  cctgacctac  tgccttgccc
1201  caagatgcag  agagagaagg  aggaatgaga  gattgagaag  ggaaagtgt  gacccctgtat  aacagtgtcc  gcagaagcaa
1281  ggggctgaaa  agatctgaag  gtcccacctc  catttgcaat  tgacctcttc  tgggaacttc  ctccagatga  caagattacc
1361  ccaccttgcc  ctttacgtat  ctgctcttag  gtgctcttcc  acttcagttg  ctttgaggga  agtgtctaga  ggaatatggt
1441  gggcacagaa  gtagctctgg  tgaccttgat  caaggtgttt  tgaaatgcag  aattcttgag  ttctggaagg  gacttttagag
1521  aataccagt  ttattaatga  caaaggcact  gaggccacgg  gaggtgacct  gaattataaa  gccagcgcc  agaaccacga
1601  tttcctaact  ctggtgtctc  ttccctttat  cagtttgact  gtggcctgtt  aactgggtata  tacatatata  tgtcaggcaa
1681  agtgtgtctg  gaagtagaat  ttgtccaata  acaggtcaac  ttccagagact  atctgatttc  ctaatgtcag  agtagaagat
1761  ttatgtctgc  tgtttacaaa  agcccaatgt  aatgcatagg  aagtatggca  tgaacatctt  taggagacta  atggaaatat
1841  tattgtgtgt  taccagtat  tccatttttt  tcatttgtgt  ctctattgct  gctctctcac  tcccccatga  ggtacagcag
1921  aaaggagaa  tatccaaaac  taatttcttc  tgacatgtaa  gacgaatgat  ttaggtacgt  caaagcagta  gtcaaggagg
2001  aaagggatag  tccaaagact  taactgggtc  atattggact  gataatctct  ttaaatggct  ttatgctagt  ttgacctcat
2081  ttgtaaaaata  ttatgagaa  agttctcatt  taaaatgaga  tcgttgttta  cagtgatagt  actaagcagt  aagctatctt
2161  caaatgtcta  aggtagtaac  ttcccatagg  gcctcccttag  atccctaaga  tggctttttc  tccttggtat  tcttggtgtc
2241  ttctgacatc  agcagagaac  tggaaaagaca  tagccaactg  ctgttcatgt  tactcatgac  tcctttctct  aaaactgcct
2321  tccacaattc  actagaccag  aagtggacgc  aacttaagct  gggaataatca  cattatcatc  tgaataatctg  gagtgaaca
2401  gcaaaaagaag  acaacatttc  tcaaatgcac  atctcatggc  agctaagcca  catggctggg  atttaagcc  tttagagcca
2481  gcccatggct  ttagctacct  cactatgctg  cttcacaaac  cttgctcctg  tgtaaaaacta  tattctcagt  gtagggcaga
2561  gaggtctaac  accaacataa  ggtactagca  gtgtttcccg  tattgacagg  aataactaac  tcaataattc  ttttctttc
2641  catttagtaa  cagttgtgat  gactatgttt  ctattctaag  taattcctgt  attctacagc  agatactttg  tcagcaatac
2721  taagggaaga  acaaaagtgt  aaccgtttct  ttaataa  (SEQ ID NO:5)

```

**FIGURE 12B**

```

1  MGHTRRQGT  PSKCPYLNFF  QLLVLAGLSH  FCSGVIHVTK  EVKEVATLSC  GHNVSVEELA
61  QTRIYWQKEK  KMVLTMMSGD  MNIWPEYKNR  TIFDITNNLS  IVILALRPSD  EGTYESVVLK
121  YEKDAFKREH  LAEVTLSVKA  DFPTPSISDF  EIPTSNIRRI  ICSTSGGFPE  PHLSWLENGE
181  ELNAINTTVS  QDPETELYAV  SSKLDFNMTT  NHSEFMCLIKY  GHLRVNQTFN  WNTTKQEHFP
241  DNLLPSWAIT  LISVNGIFVI  CCLTYCFAPR  CRERRNERL   RRESVRPV   (SEQ ID NO:6)

```

FIGURE 13

CD8<sup>+</sup> T cells




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17A




FIGURE 17B




FIGURE 18




FIGURE 19




FIGURE 20




FIGURE 21




FIGURE 22





FIGURE 23



## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 2013090552 A1 [0004]
- US 5530101 A [0031]
- US 5565332 A [0031]
- US 5585089 A [0031]
- US 5639641 A [0031]
- US 5693761 A [0031]
- US 5693762 A [0031]
- US 5733743 A [0031]
- US 4816567 A [0031]
- US 4935496 A [0031]
- US 5502167 A [0031]
- US 5558864 A [0031]
- US 5693493 A [0031]
- US 5698417 A [0031]
- US 5705154 A [0031]
- US 5750078 A [0031]
- US 5770403 A [0031]
- US 61885218 B [0080]

## Non-patent literature cited in the description

- GIBBONS et al. *Oncolmunology*, 2012, vol. 1 (7), 1061-1073 [0002]
- GRIVENNIKOV et al. *Cell*, 2010, vol. 140, 883-899 [0002]
- TOPALIAN SL et al. *The New England Journal of Medicine*, 28 June 2012, vol. 366 (26), 2443-2454 [0004]
- BERRIEN-ELLIOT MM et al. *Cancer Research*, 15 January 2013, vol. 73, 605-616 [0005]
- GIBBONS RM et al. *Oncoimmunology*, 01 October 2012, vol. 1, 1061-1073 [0006]
- JONES et al. *Nature*, 1986, vol. 321, 522-525 [0021]
- RIECHMANN et al. *Nature*, 1988, vol. 332, 323-329 [0021]
- PRESTA. *Curr. Op. Struct. Biol.*, 1992, vol. 2, 593-596 [0021]
- MORRISON et al. *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 6851-6855 [0021]
- HOLLINGER et al. *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0021]
- The Pharmacology of Monoclonal Antibodies. Springer Verlag, 1994, vol. 113, 269-315 [0021]
- MUYLDERMANS et al. *Rev. Mol. Biotechnol.*, 2001, vol. 74, 277-302 [0025]
- HOLT et al. *Trends Biotechnol.*, 2003, vol. 21, 484-90 [0025]
- KONIECZNY et al. *Haematologia (Budap.)*, 1981, vol. 14, 95 [0029]
- MORRISON et al. *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 6851 [0029]
- JONES et al. *Nature*, 1986, vol. 321, 522 [0030]
- RIECHMANN et al. *Nature*, 1988, vol. 332, 323 [0030]
- Remington's Pharmaceutical Sciences. Mack Publishing Company, 1990 [0034]
- BALDRICK. *Regul. Toxicol. Pharmacol.*, 2000, vol. 32, 210-218 [0034]
- WANG. *Int. J. Pharm.*, 2000, vol. 203, 1-60 [0034]
- CHARMAN. *J. Pharm. Sci.*, 2000, vol. 89, 967-978 [0034]
- POWELL et al. *PDA J. Pharm. Sci. Technol.*, 1998, vol. 52, 238-311 [0034]
- DONG et al. *Immunity*. Yale University, 2004, vol. 20, 327-336 [0047]
- GERDES et al. *J. Immunol.*, 1984, vol. 133, 1710-1715 [0061]
- JAYARAMAN. *J. Immunol. Methods*, 2005, vol. 306, 68-79 [0062]
- HIRANO et al. *Cancer Res*, 2005, vol. 65, 1089-1096 [0065]
- PARK et al. *Blood*, 2010, vol. 116, 1291-1298 [0065]
- ALLIE et al. *J. Immunol.*, 2011, vol. 186, 6280-6286 [0066]
- QI et al. *J. Biol. Chem.*, 2006, vol. 281, 813-823 [0069]
- SARBASSOV et al. *Science*, 2005, vol. 307, 1098-1101 [0069]
- JACINTO et al. *Cell*, 2006, vol. 127, 125-137 [0069]

|                |                                                                                                                                                                  |         |            |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|------------|
| 专利名称(译)        | 治疗BIM水平升高的患者的癌症的方法                                                                                                                                               |         |            |
| 公开(公告)号        | <a href="#">EP3052131A1</a>                                                                                                                                      | 公开(公告)日 | 2016-08-10 |
| 申请号            | EP2014850189                                                                                                                                                     | 申请日     | 2014-09-03 |
| [标]申请(专利权)人(译) | 梅约医学教育与研究基金会                                                                                                                                                     |         |            |
| 申请(专利权)人(译)    | 梅奥基金会的医学教育和研究                                                                                                                                                    |         |            |
| 当前申请(专利权)人(译)  | 梅奥基金会的医学教育和研究                                                                                                                                                    |         |            |
| [标]发明人         | DONG HAIDONG<br>HARRINGTON SUSAN M<br>KWON EUGENE D<br>KRCO CHRISTOPHER J<br>LIU XIN                                                                             |         |            |
| 发明人            | DONG, HAIDONG<br>HARRINGTON, SUSAN M.<br>KWON, EUGENE D.<br>KRCO, CHRISTOPHER J.<br>LIU, XIN                                                                     |         |            |
| IPC分类号         | A61K39/395 A61K39/00 G01N33/53 C12Q1/68 C07K16/28                                                                                                                |         |            |
| CPC分类号         | A61K2039/505 A61P35/00 C07K16/2818 C07K16/2827 C07K2317/76 C12Q1/6886 C12Q2600/106 C12Q2600/158 G01N33/57407 G01N33/57484 G01N2333/70532 G01N2800/52 G01N2333/47 |         |            |
| 优先权            | 61/885218 2013-10-01 US                                                                                                                                          |         |            |
| 其他公开文献         | EP3052131B1<br>EP3052131A4                                                                                                                                       |         |            |
| 外部链接           | <a href="#">Espacenet</a>                                                                                                                                        |         |            |

#### 摘要(译)

用于治疗癌症的材料和方法，包括用于治疗被鉴定为具有升高的Bim水平的患者的癌症的材料和方法。